On the Regulation and Control of Fibrinolysis

Thrombosis and Haemostasis

43, 077-089

DOI: 10.1055/s-0038-1650023

Citation Report

#	Article	IF	Citations
1	New Strategies in the Development of Thrombolytic Agents. Current Studies in Hematology and Blood Transfusion, 1991, 58, 69-72.	0.2	1
2	Impaired fibrinolytic response to DDAVP and venous occlusion in a sub-group of patients with von Willebrand's disease. Thrombosis Research, 1981, 23, 365-374.	0.8	11
3	Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochimica Et Biophysica Acta - General Subjects, 1981, 673, 75-85.	1.1	206
4	SPECIFIC LYSIS OF AN ILIOFEMORAL THROMBUS BY ADMINISTRATION OF EXTRINSIC (TISSUE-TYPE) PLASMINOGEN ACTIVATOR. Lancet, The, 1981, 318, 1018-1020.	6.3	136
5	Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of Î± 2-plasmin inhibitor. Biochemical Journal, 1981, 199, 121-127.	1.7	37
6	Plasma Kallikrein and Plasmin as Activators of Prorenin: Links between the Renin-Angiotensin System and other Proteolytic Systems in Plasma. Clinical Science, 1981, 61, 15-21.	1.8	35
7	ABNORMAL FIBRINOLYSIS IN RETINAL VEIN OCCLUSION. Australian and New Zealand Journal of Ophthalmology, 1981, 9, 213-218.	0.4	4
8	On the Rolw of the Carbohydrate Side Chains of Human Plasminogen in Its Interaction with alpha2-Antiplasmin and Fibrin. FEBS Journal, 1981, 120, 149-154.	0.2	64
9	Thrombosis: a molecular approach to therapy. Nature, 1981, 290, 445-446.	13.7	8
10	Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators.. Journal of Cell Biology, 1982, 94, 631-636.	2.3	369
11	Activation of Plasma Prorenin by Plasminogen Activators in Vitro and Increase in Plasma Renin After Stimulation of Fibrinolytic Activity in Vivo. Clinical and Experimental Hypertension, 1982, 4, 2247-2258.	0.3	2
12	The Biology of Thrombosis. Annual Review of Medicine, 1982, 33, 479-488.	5.0	13
13	INCREASED BLOOD VISCOSITY AND FIBRINOLYTIC INHIBITOR IN TYPE II HYPERLIPOPROTEINAEMIA. Lancet, The, 1982, 319, 472-475.	6.3	82
14	Urokinase therapy for a catheter-related right atrial thrombus. Journal of Pediatrics, 1982, 100, 149-152.	0.9	83
15	A study of hemostasis in ischemic cerebrovascular disease III. Abnormalities in vascular plasminogen activators, antiactivators and Î±2-antiplasmin. Thrombosis Research, 1982, 26, 203-210.	0.8	38
16	Measurement in human blood of fibrinogen/fibrin fragments containing the bÎ² 15â€“42 sequence. Thrombosis Research, 1982, 25, 277-291.	0.8	99
17	Proteolysis of fibrinogen in healthy volunteers following major and minor in vivo plasminogen activation. Thrombosis Research, 1982, 27, 91-97.	0.8	8
18	Thrombin-like snake venom proteinases. Toxicon, 1982, 20, 265-273.	0.8	72

#	Article	IF	Citations
19	Stability of Proteins. Advances in Protein Chemistry, 1982, 35, 1-104.	4.4	733
21	Selected Hemostatic Abnormalities Associated with Neoplastic Disease. Clinics in Laboratory Medicine, 1982, 2, 599-625.	0.7	0
22	Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells. BBA - Proteins and Proteomics, 1982, 703, 113-115.	2.1	33
23	Release of fibrinolytic activators from the cornea and conjunctiva. Graefe's Archive for Clinical and Experimental Ophthalmology, 1982, 219, 263-267.	1.0	16
24	PLASMIN-Î±2-ANTIPLASMIN COMPLEX AS AN INDICATOR OF IN VIVO FIBRINOLYSIS. British Journal of Haematology, 1982, 50, 537-541.	1.2	20
25	Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature, 1983, 301, 214-221.	13.7	1,288
26	A 1H-NMR study of isolated domains from human plasminogen Structural homology between kringles 1 and 4. FEBS Journal, 1983, 135, 379-391.	0.2	38
27	Identification of a site in fibrin(OGEN) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. BBA - Proteins and Proteomics, 1983, 748, 86-92.	2.1	85
28	Analysis of the effects of snake venom proteinases on the activity of human plasma C1 esterase inhibitor, Î±1-antichymotrypsin and Î±2-antiplasmin. BBA - Proteins and Proteomics, 1983, 745, 113-120.	2.1	35
29	Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Seminars in Immunopathology, 1983, 6-6, 231-58.	4.0	52
30	Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. Biochimica Et Biophysica Acta - General Subjects, 1983, 755, 531-533.	1.1	107
31	Differences in effects of fibrin(ogen) fragments on the activation of 1-glu-plasminogen and 442-VAL-plasminogen by tissue-type plasminogen activator. Thrombosis Research, 1983, 32, 87-92.	0.8	23
32	Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thrombosis Research, 1983, 31, 427-436.	0.8	474
33	Tissue plasminogen activator in human plasma measured by radioimmunoassay. Thrombosis Research, 1983, 31, 461-474.	0.8	27
34	A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. Molecular Immunology, 1983, 20, 1191-1200.	1.0	57
35	Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. American Journal of Medicine, 1983, 74, 33-39.	0.6	101
36	Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clinica Chimica Acta, 1983, 127, 279-288.	0.5	253
37	THE OCCURRENCE AND CLINICAL RELEVANCE OF FIBRIN FRAGMENTS IN BLOOD. Annals of the New York Academy of Sciences, 1983, 408, 407-423.	1.8	36

#	Article	IF	Citations
38	Determination of tissue plasminogen activator by an enzyme-immunoassay method. Analytical Biochemistry, 1983, 135, 58-63.	1.1	18
39	Enzyme-protein conjugates: new possibilities for enzyme therapy. , 1983, 21, 53-76.		15
40	Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science, 1983, 220, 1181-1183.	6.0	239
41	Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections. Journal of Neurosurgery, 1983, 58, 242-245.	0.9	70
42	Vessel injury, platelet adherence, and platelet survival.. Arteriosclerosis (Dallas, Tex), 1983, 3, 529-546.	4.9	67
43	Systemic thrombolytic therapy of acute myocardial infarction?. Circulation, 1983, 68, 462-465.	1.6	64
44	Isolation of cDNA sequences coding for a part of human tissue plasminogen activator.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 349-352.	3.3	68
45	Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 2956-2960.	3.3	360
46	Antithrombin III and Plasminogen: A Comparison of Two Synthetic Substrate-based Methods. American Journal of Clinical Pathology, 1983, 80, 465-473.	0.4	3
47	Urokinase therapy for thrombosis of tricuspid prosthetic valve. Journal of Thoracic and Cardiovascular Surgery, 1983, 85, 935-937.	0.4	29
48	Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood, 1983, 61, 476-482.	0.6	50
49	Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. Blood, 1983, 62, 62-68.	0.6	54
50	The mechanism of in vitro clot lysis induced by vascular plasminogen activator. Blood, 1984, 63, 1331-1337.	0.6	20
51	Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.. EMBO Journal, 1984, 3, 51-56.	3.5	76
52	Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.. Journal of Cell Biology, 1984, 99, 753-757.	2.3	166
53	New approaches to thrombolytic therapy.. Arteriosclerosis (Dallas, Tex), 1984, 4, 579-585.	4.9	43
54	Consumption of fibrinolytic proteins in menstrual fluid from women with normal menstrual blood loss.. Journal of Clinical Pathology, 1984, 37, 879-881.	1.0	17
55	Warfarin. New England Journal of Medicine, 1984, 311, 645-652.	13.9	146

#	Article	IF	Citations
56	Enzymatic inactivation of human plasma C-inhibitor and Î±1-antichymotrypsin by pseudomonas aeruginosa proteinase and elastase. BBA - Proteins and Proteomics, 1984, 789, 37-43.	2.1	40
57	Inhibition of the Late Phase Reaction to Anti-Human IgE in Man by Oral Tranexamic Acid. Allergy: European Journal of Allergy and Clinical Immunology, 1984, 39, 115-118.	2.7	8
58	Plasmin-a2-antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis. British Journal of Haematology, 1984, 56, 545-556.	1.2	44
59	Molecular biology of plasminogen activators and recombinant DNA progress. BioEssays, 1984, 1, 168-173.	1.2	5
60	Reverse fibrin autography: A method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analytical Biochemistry, 1984, 137, 454-463.	1.1	172
61	The fibrinolytic system in man. Critical Reviews in Oncology/Hematology, 1984, 2, 33-81.	2.0	10
62	Studies of four Japanese families with hereditary angioneurotic edema: Simultaneous activation of plasma protease systems and exogenous triggering stimuli. Blut, 1984, 49, 405-418.	1.2	14
63	Enzymatic inactivation of human -antichymotrypsin by metalloproteinases in snake venoms of the family elapidae. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1984, 77, 431-436.	0.2	3
64	Immunological identification of plasminogen activators in normal and malignant tissues of the oral cavity in man. International Journal of Oral Surgery, 1984, 13, 334-338.	0.6	9
65	Toxicological assessment of the hemostatic system, regulatory requirements, and industry practice. Regulatory Toxicology and Pharmacology, 1984, 4, 74-95.	1.3	13
66	Degradation of serum amyloid A and apolipoproteins by serum proteases. Biochemistry, 1984, 23, 2241-2245.	1.2	20
67	Cooperative association of plasminogen with fibrinogen. Biochemistry, 1984, 23, 3874-3879.	1.2	20
68	Human endothelial cells contain one type of plasminogen activator. FEBS Letters, 1984, 168, 33-37.	1.3	147
69	Plasminogen activator activity in differentiating leukemia cells. FEBS Letters, 1984, 177, 66-70.	1.3	9
70	Coronary thrombolysis: Pharmacological considerations with emphasis on tissue-type plasminogen activator (t-PA). Biochemical Pharmacology, 1984, 33, 1831-1838.	2.0	25
71	Thrombolytic therapy for acute transmural myocardial infarction. American Journal of Medicine, 1984, 77, 921-928.	0.6	27
72	Monitoring activity of fibrinolytic agents. American Journal of Medicine, 1984, 76, 879-886.	0.6	42
73	Domains in human plasminogen. Journal of Molecular Biology, 1984, 179, 215-232.	2.0	107

#	Article	IF	Citations
74	A direct, plasmin-independent assay for plasminogen activator. Thrombosis Research, 1984, 34, 241-254.	0.8	28
75	A sensitive assay for tissue plasminogen activator activity in plasma, using adsorption on lysine-sepharose. Thrombosis Research, 1984, 35, 547-558.	0.8	26
76	A hypothalamic-pituitary system that stimulates the release of plasminogen activator in the rat. Brain Research, 1984, 299, 133-138.	1.1	10
77	Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochimica Et Biophysica Acta - General Subjects, 1984, 802, 99-110.	1.1	114
78	The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 5355-5359.	3.3	300
79	Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator. Biochemical Journal, 1984, 223, 179-187.	1.7	45
80	Zymogen-activation kinetics. Modulatory effects of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid and poly-d-lysine on plasminogen activation. Biochemical Journal, 1985, 225, 149-158.	1.7	36
81	Plasmin activity and proteose-peptone content of individual milks. Journal of Dairy Research, 1985, 52, 369-378.	0.7	70
82	Intraoperative Changes in Blood Coagulation and Thrombelastographic Monitoring in Liver Transplantation. Anesthesia and Analgesia, 1985, 64, 888???896.	1.1	565
83	Lysis of intracranial hematomas with urokinase in a rabbit model. Journal of Neurosurgery, 1985, 62, 580-586.	0.9	58
84	Studies of 99mTc-acylplasmins as agents for thrombus detection. European Journal of Nuclear Medicine and Molecular Imaging, 1985, 10-10, 155-9.	2.2	3
85	Proton Overhauser experiments on kringle 4 from human plasminogen. Implications for the structure of the kringles' hydrophobic core. BBA - Proteins and Proteomics, 1985, 827, 369-380.	2.1	24
86	Dental extractions in hemophilia: Reflections on 10 years' experience. Oral Surgery, Oral Medicine, and Oral Pathology, 1985, 59, 6-9.	0.6	25
87	Thrombolytic Treatment with Recombinant Tissue-Type Plasminogen Activator in a Patient with Massive Pulmonary Embolism. Annals of Internal Medicine, 1985, 103, 64.	2.0	49
88	Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland.. Journal of Cell Biology, 1985, 101, 305-311.	2.3	59
89	Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood, 1985, 66, 423-427.	0.6	56
90	Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood, 1985, 66, 399-401.	0.6	68
91	Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood, 1985, 65, 32-40.	0.6	210

#	Article	IF	Citations
92	Catabolism of human tissue plasminogen activator in mice. Blood, 1985, 65, 539-544.	0.6	114
93	Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood, 1985, 66, 835-839.	0.6	171
94	Production of monoclonal antibodies to the high fibrin-affinity, tissue- type plasminogen activator of human plasma. Demonstration of its endothelial origin by immunolocalization. Blood, 1985, 66, 913-920.	0.6	33
95	CULTURED GRANULOSA CELLS PRODUCE TWO PLASMINOGEN ACTIVATORS AND AN ANT IACTIVATOR, EACH REGULATED DIFFERENTLY BY GONADOTROPINS.. Endocrinology, 1985, 116, 1666-1668.	1.4	183
96	Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.. Circulation, 1985, 72, 1346-1354.	1.6	90
97	Plasminogen Activators, Tissue Degradation, and Cancer. Advances in Cancer Research, 1985, 44, 139-266.	1.9	2,307
98	Platelet release protein which inhibits plasminogen activators.. Journal of Clinical Pathology, 1985, 38, 825-830.	1.0	73
99	Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug. Angiology, 1985, 36, 387-398.	0.8	88
101	The Current and Future use of Thrombolytic Therapy. Annual Review of Pharmacology and Toxicology, 1985, 25, 413-431.	4.2	17
102	Cloning and Expression of the Gene for Pro-urokinase in Escherichia coli. Bio/technology, 1985, 3, 923-929.	1.9	217
104	Molecular Cloning, Sequencing, and Expression inEscherichia coliof Human Preprourokinase cDNA. DNA and Cell Biology, 1985, 4, 139-146.	5.1	23
105	Clinical Application of Inhibitors of Fibrinolysis. Drugs, 1985, 29, 236-261.	4.9	407
106	RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION. Lancet, The, 1985, 325, 842-847.	6.3	726
107	Tissue-type plasminogen activator (t-PA): an agent with promise for selective thrombolysis. International Journal of Cardiology, 1985, 7, 82-86.	0.8	8
109	Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thrombosis Research, 1985, 39, 1-8.	0.8	126
110	The plasma inhibitors of plasminogen activator, studied by a zymographic technique. Thrombosis Research, 1985, 38, 261-267.	0.8	18
111	Quantitative analysis of the composition of mixtures of one-chain and two-chain tissue-type plasminogen activator with a spectrophotometric method. Thrombosis Research, 1985, 39, 281-288.	0.8	19
112	The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits. Thrombosis Research, 1985, 40, 769-777.	0.8	58

#	Article	IF	Citations
113	Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thrombosis Research, 1985, 40, 161-170.	0.8	15
114	The Classical Complement Pathway: Activation and Regulation of the First Complement Component. Advances in Immunology, 1985, 37, 151-216.	1.1	468
115	Releasable vascular plasminogen activator and thrombotic strokes. American Journal of Medicine, 1985, 79, 407-411.	0.6	18
116	Usefulness of residual plasma fibrinogen after intravenous streptokinase for predicting delay or failure of reperfusion in acute myocardial infarction. American Journal of Cardiology, 1986, 58, 680-685.	0.7	18
117	Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Letters, 1986, 196, 269-273.	1.3	59
118	Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochemical Pharmacology, 1986, 35, 3147-3150.	2.0	27
119	Epidemiology and pathogenesis of venous thrombosis. Journal of the American College of Cardiology, 1986, 8, 104B-113B.	1.2	69
120	Tissue-Type Plasminogen Activator. Drugs, 1986, 31, 1-5.	4.9	29
121	Current Issues in Thrombosis Prevention with Antiplatelet Drugs. Drugs, 1986, 31, 517-549.	4.9	32
122	Topography of the high-affinity lysine binding site of plasminogen as defined with a specific antibody probe. Biochemistry, 1986, 25, 6926-6933.	1.2	21
123	Hormonal regulation of extracellular plasminogen activators and Mr âˆ¼ 54000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Molecular and Cellular Endocrinology, 1986, 45, 137-147.	1.6	68
124	Species differences in the detection of high molecular weight urinary plasminogen activators. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1986, 84, 287-293.	0.2	9
125	Functional analysis of the human tissue-type plasminogen activator protein: the light chain. Gene, 1986, 42, 59-67.	1.0	42
126	The active and the inactive plasminogen activator inhibitor from human endothelial cell conditioned medium are immunologically and functionally related to each other. Biochimica Et Biophysica Acta - General Subjects, 1986, 883, 233-241.	1.1	21
127	Defective release of vascular plasminogen activator in patients with gynecologic malignancies. Gynecologic Oncology, 1986, 23, 141-148.	0.6	2
128	Release of BÎ² peptides from fibrinogen or fibrin in the presence of Î±2antiplasmin. Thrombosis Research, 1986, 42, 1-9.	0.8	5
129	Aspirin and venous occlusion: Effects on blood fibrinolytic activity and tissue-type plasminogen activator levels. Thrombosis Research, 1986, 42, 73-82.	0.8	17
130	Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-CAP) in plasma, platelets and endothelial cells. Thrombosis Research, 1986, 44, 503-515.	0.8	48

#	Article	IF	Citations
131	Suppression of plasminogen activator activity by dexamethasone in cultured cardiac myocytes. Journal of Molecular and Cellular Cardiology, 1986, 18, 1117-1124.	0.9	10
132	Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. Blood, 1986, 67, 1493-1497.	0.6	38
133	Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.. EMBO Journal, 1986, 5, 2539-2544.	3.5	315
134	Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids.. EMBO Journal, 1986, 5, 2217-2222.	3.5	79
135	Epsilon-Aminocaproic Acid in the Treatment of Patients with Acute Promyelocytic Leukemia and Acquired Alpha-2-Plasmin Inhibitor Deficiency. Annals of Internal Medicine, 1986, 105, 873.	2.0	106
136	Chapter 8 Fibrinolysis and thrombolysis. New Comprehensive Biochemistry, 1986, 13, 243-258.	0.1	1
137	Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6776-6780.	3.3	374
138	Autonomous functions of structural domains on human tissue-type plasminogen activator.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4670-4674.	3.3	217
139	Drugs affecting blood coagulation and hemostasis. Side Effects of Drugs Annual, 1986, 10, 310-322.	0.6	1
140	Effect of subclinical mastitis on milk plasminogen and plasmin compared with that on sodium, antitrypsin andN-acetyl-Î²-D-glucosaminidase. Journal of Dairy Research, 1986, 53, 515-528.	0.7	65
141	Stimulation of tissue plasminogen activator production from epithelial cell lines. Cell Biochemistry and Function, 1986, 4, 55-60.	1.4	4
142	Human synovial fibroblasts produce urokinase-type plasminogen activator. Arthritis and Rheumatism, 1986, 29, 1397-1401.	6.7	41
143	Interaction between leukocytes and serum plasminogen: An essential mechanism in peripheral blood fibrinolytic activity. American Journal of Hematology, 1986, 22, 233-239.	2.0	9
144	Lysis time and FDP immunoprecipitation by soluble and immobilized urokinase. Journal of Biomedical Materials Research Part B, 1986, 20, 189-203.	3.0	6
145	Structure and function of human tissue-type plasminogen activator (t-PA). Journal of Cellular Biochemistry, 1986, 32, 169-178.	1.2	83
146	Fibrinolytic system of cultured endothelial cells: Regulation by plasminogen activator inhibitor. Journal of Cellular Biochemistry, 1986, 32, 273-280.	1.2	30
147	The role of the endothelium in arterial thrombosis and the influence of antithrombotic therapy. Drug Development Research, 1986, 7, 319-340.	1.4	11
148	The use of free flow electrophoresis in the purification of recombinant human tissue plasminogen activator expressed in yeast. Electrophoresis, 1986, 7, 372-375.	1.3	17

#	Article	IF	Citations
149	Prevention of intravascular blood clotting in rats by DIP-?-thrombin. Bulletin of Experimental Biology and Medicine, 1986, 102, 1167-1169.	0.3	0
150	Tissue-type plasminogen activator in rat adrenal medulla. Histochemistry, 1986, 85, 431-436.	1.9	47
151	The fibrinolytic system in man. Critical Reviews in Oncology/Hematology, 1986, 4, 249-301.	2.0	90
152	Fibrinogen and fibrin: Biochemistry and pathophysiology. Critical Reviews in Oncology/Hematology, 1986, 6, 97-146.	2.0	61
153	Polyunsaturated fatty acids increase fibrinolytic activity of human isolated glomeruli. Kidney International, 1986, 30, 701-705.	2.6	13
154	A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis. FEBS Journal, 1986, 157, 65-69.	0.2	7
155	Monoclonal antibodies inhibitory to human plasmin. Definitive demonstration of a role for plasmin in activating the proenzyme of urokinase-type plasminogen activator. FEBS Journal, 1986, 158, 537-542.	0.2	23
156	Streptokinase, urokinase, and tissue plasminogen activator: Pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis. CardioVascular and Interventional Radiology, 1986, 9, 236-244.	0.9	8
157	Enzyme-Linked Immunosorbent Assay for Human Urokinase-Type Plasminogen Activator and its Proenzyme Using a Combination of Monoclonal and Polyclonal Antibodies. Journal of Immunoassay, 1986, 7, 209-228.	0.3	45
158	Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.. Circulation, 1986, 74, 1027-1036.	1.6	30
159	Synergism of thrombolytic agents in vivo.. Circulation, 1986, 74, 838-842.	1.6	115
160	The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.. Journal of Cell Biology, 1986, 103, 2411-2420.	2.3	462
161	Chapter 1 Blood coagulation as a part of the haemostatic system. New Comprehensive Biochemistry, 1986, 13, 1-13.	0.1	5
162	Thrombolysis and Stroke. Archives of Neurology, 1987, 44, 748.	4.9	134
163	Tissue-Type Plasminogen Activator in Somatostatin Cells of Rat Pancreas and Hypothalamus*. Endocrinology, 1987, 121, 2238-2244.	1.4	28
164	A Modified Human Tissue Plasminogen Activator with Extended Halfâ€“Life In Vivo. Nature Biotechnology, 1987, 5, 953-958.	9.4	36
165	Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.. Journal of Cell Biology, 1987, 104, 705-712.	2.3	142
166	Review article : Blood compatibility of cardiopulmonary bypass circuits. Perfusion (United Kingdom), 1987, 2, 237-244.	0.5	21

#	Article	IF	Citations
167	Hormonal and Immunological Characterization of the Cell-Associated Plasminogen Activators Produced by Cultured Rat Granulosa Cells. Endocrinology, 1987, 120, 2174-2179.	1.4	6
168	Prevention of Clot Formation in Cat Retinal Vein by Systemic and Subconjunctival Urokinase. JAMA Ophthalmology, 1987, 105, 554-558.	2.6	5
169	Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. Journal of Cell Biology, 1987, 104, 1085-1096.	2.3	298
170	Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor.. Journal of Experimental Medicine, 1987, 166, 77-94.	4.2	73
171	The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro. Biochemical Journal, 1987, 247, 395-400.	1.7	23
172	Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.. Annals of the Rheumatic Diseases, 1987, 46, 741-745.	0.5	44
173	Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8548-8552.	3.3	127
174	Tissue Plasminogen Activator: An Evaluation of Clinical Efficacy in Acute Myocardial Infarction. Pharmacotherapy, 1987, 7, 111-120.	1.2	8
175	Production of tissue plasminogen activators from animal cells. , 1987, 34, 147-166.		19
176	Characterization of astrocyte plasminogen activator. Journal of the Neurological Sciences, 1987, 80, 277-287.	0.3	17
177	The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class pai-2 inhibitor (minactivin). Thrombosis Research, 1987, 46, 755-766.	0.8	18
178	Poly-d-lysine dependent inactivation of tissue plasminogen activator by a class pai-2 inhibitor (minactivin). Thrombosis Research, 1987, 46, 767-777.	0.8	7
179	Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies. Thrombosis Research, 1987, 46, 411-423.	0.8	10
180	Measurement of tissue plasminogen activator in plasma. a comparison of 3 methods and description of a new improved technique. Thrombosis Research, 1987, 46, 213-223.	0.8	15
181	Mini-plasminogen like molecule in septic patients. Thrombosis Research, 1987, 47, 553-560.	0.8	13
182	Evolution of Thrombosis. Annals of the New York Academy of Sciences, 1987, 516, 586-604.	1.8	10
183	Distribution of Tissue Plasminogen Activator in Human and Monkey Eyes. Ophthalmology, 1987, 94, 1434-1438.	2.5	47
184	cDNA cloning and expression inE.coliof a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Letters, 1987, 210, 11-16.	1.3	50

#	Article	IF	Citations
185	Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. American Journal of Medicine, 1987, 83, 15-19.	0.6	87
186	Molecular mechanism of action of newer thrombolytic agents. Journal of the American College of Cardiology, 1987, 10, 11B-15B.	1.2	31
187	Acute coronary artery obstruction in myocardial infarction: Overview of thrombolytic therapy. Journal of the American College of Cardiology, 1987, 9, 1375-1384.	1.2	32
188	Photoaffinity labeling of human plasmin and plasminogen. , 1987, 34, 335-348.		4
189	Tissue plasminogen activator in avascular tissues of the eye: a quantitative study of its activity in the cornea, lens, and aqueous and vitreous humors of dog, calf, and monkey. Experimental Eye Research, 1987, 44, 55-63.	1.2	35
190	Tissue plasminogen activator (tPA) as a reporter gene in transient gene expression. Gene, 1987, 58, 299-303.	1.0	9
191	International Committee for Fibrinolysisâ€"Kabi Prize Lecture 1986. Fibrinolysis, 1987, 1, 3-12.	0.5	20
192	Pregnancy-induced changes in the fibrinolytic balance: Evidence for defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor. American Journal of Obstetrics and Gynecology, 1987, 156, 674-680.	0.7	36
193	Proton magnetic resonance study of lysine-binding to the kringle 4 domain of human plasminogen. Journal of Molecular Biology, 1987, 198, 481-498.	2.0	58
194	Myocardial tissue salvage by coronary thrombolysis with rt-PA: Absence of occlusion/reperfusion injury. Fibrinolysis, 1987, 1, 155-162.	0.5	3
195	Thrombolytic Therapy for Venous Thrombosis. Annals of Vascular Surgery, 1987, 1, 521-523.	0.4	2
196	Treatment of mouse L-cells with phorbol myristate acetate induces the secretion of a plasminogen activator inhibitor which binds to human and mouse urokinase and human tissue plasminogen activator. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1987, 88, 277-283.	0.2	2
197	Adverse Reactions to Thrombolytic Agents. Medical Toxicology, 1987, 2, 274-286.	1.7	10
198	Thrombolytic Therapy in Acute Myocardial Infarction. Drugs, 1987, 33, 1-12.	4.9	9
199	Physiological Balance of Haemostasis and Bleeding. Drugs, 1987, 33, 13-21.	4.9	7
200	Anisoylated Plasminogen Streptokinase Activator Complex (APSAC). Drugs, 1987, 34, 25-49.	4.9	55
201	Purification and characterization of a tissue plasminogen activator-inhibitor complex from human umbilical vein endothelial cell conditioned medium. Biochemistry, 1987, 26, 7443-7449.	1.2	12
202	Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.. EMBO Journal, 1987, 6, 1281-1286.	3.5	229

#	Article	IF	Citations
203	Comparative thrombolytic properties of single-chain forms of urokinase- type plasminogen activator. Blood, 1987, 69, 592-596.	0.6	30
204	Immunoradiometric quantitation of tissue plasminogen activator-related antigen in human plasma: crypticity phenomenon and relationship to plasma fibrinolysis. Blood, 1987, 69, 1348-1353.	0.6	8
205	The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood, 1987, 70, 343-350.	0.6	415
206	Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level. Blood, 1987, 69, 1354-1362.	0.6	62
207	Clinical Pharmacology of Coronary Thrombolysis. Cardiology Clinics, 1987, 5, 125-128.	0.9	1
208	Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood, 1987, 70, 721-728.	0.6	188
209	Enhancedin vitro fibrinolytic activity of immobilized plasmin on collagen beads. Journal of Biomedical Materials Research Part B, 1987, 21, 897-912.	3.0	8
210	Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Journal of Cellular Biochemistry, 1987, 33, 77-86.	1.2	95
211	Tissue-type plaminogen activator and urokinase: differences in the reaction pattern with the active-site titrant 4-methylumbelliferyl-p-guanidinobenzoate hydrochloride. BBA - Proteins and Proteomics, 1987, 912, 34-40.	2.1	15
212	Immunohistochemical Localization of Urokinase- and Tissue-Type Plasminogen Activators in Psoriatic Skin. Journal of Investigative Dermatology, 1987, 88, 28-32.	0.3	99
213	Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. FEBS Journal, 1987, 165, 595-600.	0.2	47
214	Effect of the cyanogen-bromide-2 fragment of fibrinogen on plasminogen activation by single-chain urokinase-type plasminogen activator. FEBS Journal, 1987, 166, 393-397.	0.2	6
215	Recombinant tissue plasminogen activator: a brief review. Pharmaceutical Research, 1987, 04, 375-378.	1.7	104
216	Haemostatic disturbances in patients bitten by Russell's viper (Vipera russelli siamensis) in Burma. British Journal of Haematology, 1988, 69, 513-520.	1.2	59
217	Plasminogen activator inhibitor (PAIâ€1) in plasma and platelets. British Journal of Haematology, 1988, 70, 327-333.	1.2	284
218	Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP) I. CHARACTERIZATION AND PRELIMINARY EVALUATION IN PLASMA. British Journal of Haematology, 1988, 68, 83-90.	1.2	25
219	Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP) II. EVALUATION IN A VARIETY OF CLINICAL CONDITIONS. British Journal of Haematology, 1988, 68, 91-96.	1.2	58
220	Endotoxinâ€induced Mastitis Inhibition of Casein Synthesis and Activation of the Caseinolytic System. Zoonoses and Public Health, 1988, 35, 353-360.	1.4	18

#	Article	IF	Citations
221	The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Annals of Neurology, 1988, 23, 391-394.	2.8	50
222	Plasmin-Î±2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. American Journal of Hematology, 1988, 28, 162-166.	2.0	44
223	The determination of recombinant human tissue-type plasminogen activator activity by turbidimetry using a microcentrifugal analyzer. Analytical Biochemistry, 1988, 168, 428-435.	1.1	39
224	Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: Quantitative expression of active and proenzyme. International Journal of Cancer, 1988, 42, 483-488.	2.3	40
225	Emergency thrombolysis in acute myocardial infarction. Annals of Emergency Medicine, 1988, 17, 1168-1175.	0.3	8
226	New strategies in the development of thrombolytic agents. Blut, 1988, 57, 147-162.	1.2	11
227	Haemostatic variables, serum lipid abnormalities and vascular complications in diabetes mellitus: a 5 year follow-up study. Blut, 1988, 56, 257-260.	1.2	4
228	Analysis of the plasminogen activator activity of the human glomerulus. Kidney International, 1988, 33, 868-874.	2.6	12
229	Pharmacodynamic and Systemic Fibrinolytic Effects of Plasminogen Activators in Man. Journal of Interventional Cardiology, 1988, 1, 149-159.	0.5	1
230	Urokinase- and Tissue-Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization In Vivo. Journal of Investigative Dermatology, 1988, 90, 790-795.	0.3	205
231	Vascular endothelium, haemostasis and thrombosis. Blood Reviews, 1988, 2, 88-94.	2.8	28
232	Dissimilar systemic and local adverse effects of thrombolytic therapy. American Journal of Cardiology, 1988, 61, 1344-1346.	0.7	9
233	A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry, 1988, 27, 1067-1074.	1.2	166
234	Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins. Biochemistry, 1988, 27, 2565-2572.	1.2	51
235	Bovine plasminogen activator inhibitor 1: Specificity determinations and comparison of the active, latent, and guanidine-activated forms. Biochemistry, 1988, 27, 2911-2918.	1.2	84
236	Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Archives of Biochemistry and Biophysics, 1988, 262, 199-210.	1.4	155
237	Immunohistochemical localization of urokinase-type plasminogen activator in sertoli cells and tissue-type plasminogen activator in spermatogenic cells in the rat seminiferous epithelium. Developmental Biology, 1988, 126, 150-155.	0.9	45
238	Changes in various parameters of fibrinolysis in persons infused with tissue plasminogen activator: Special reference to plasminogen activator inhibitor. Thrombosis Research, 1988, 50, 23-33.	0.8	3

#	Article	IF	Citations
239	Role of Degradative Enzymes in Wound Healing. , 1988, , 497-523.		10
241	Changes in various parameters of fibrinolysis in persons infused with tissue plasminogen activator: Special reference to plasminogen activator inhibitor. Thrombosis Research, 1988, 49, 23-33.	0.8	1
242	Aprotinin inhibits urokinase but not tissue-type plasminogen activator. Thrombosis Research, 1988, 49, 549-556.	0.8	34
243	Distribution of plasminogen activators in human kidney and male genital organs using a highly sensitive enzyme immunoassay. Thrombosis Research, 1988, 51, 453-459.	0.8	19
244	Tissue-type plasminogen activator in the chronic subdural hematoma. World Neurosurgery, 1988, 30, 175-179.	1.3	63
245	Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. Biochimica Et Biophysica Acta - General Subjects, 1988, 967, 183-194.	1.1	75
246	Cloning and Characterization of a cDNA for Rat Tissue-Type Plasminogen Activator. DNA and Cell Biology, 1988, 7, 671-677.	5.1	55
247	Specific cleavage of diphtheria toxin by human urokinase. Biochemical and Biophysical Research Communications, 1988, 157, 747-754.	1.0	17
248	Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells. Biochemical and Biophysical Research Communications, 1988, 155, 418-422.	1.0	35
249	Tissue-type plasminogen activator inhibits aggregation of platelets. Life Sciences, 1988, 43, 955-963.	2.0	19
250	Streptokinase-induced, antibody-mediated platelet aggregation: A potential cause of clot propagation in vivo. Journal of the American College of Cardiology, 1988, 11, 1343-1348.	1.2	39
251	Unresolved clinical pharmacologic questions in thrombolytic therapy for acute myocardial infarction. Journal of the American College of Cardiology, 1988, 12, 519-525.	1.2	16
252	Tissue Plasminogen Activator. New England Journal of Medicine, 1988, 319, 925-931.	13.9	211
253	Effect of fibrinogen-clotting enzymes on secretion of plasminogen activators from cultured human endothelial cells. Fibrinolysis, 1988, 2, 49-57.	0.5	6
254	Construction and expression of a hybrid plasminogen activator gene with sequences from non-protease region of tissue-type plasminogen activator (t-PA) and protease region of urokinase (u-PA). Gene, 1988, 68, 205-212.	1.0	3
255	Effect of activated protein c on the fibrinolytic components released by cultured bovine aortic endothelial cells. Fibrinolysis, 1988, 2, 7-15.	0.5	8
256	Regulation of fibrinolysis in aortic surgery. Journal of Vascular Surgery, 1988, 8, 384-388.	0.6	14
257	Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1988, 90, 691-708.	0.2	48

#	Article	IF	Citations
258	Effect of viscous macromolecules on peritoneal plasminogen activator activity: A potential mechanism for their ability to reduce postoperative adhesion formation. American Journal of Obstetrics and Gynecology, 1988, 159, 957-963.	0.7	31
259	Persistent decreased fibrinolytic activity in cyclosporin-treated renal allograft recipients. Fibrinolysis, 1988, 2, 197-201.	0.5	12
260	Mutants of human tissue-type plasminogen activator (t-PA): Structural aspects and functional properties. Fibrinolysis, 1988, 2, 123-132.	0.5	65
261	Enhanced plasminogen activator activity in vascular cells treated with propranolol. Fibrinolysis, 1988, 2, 215-221.	0.5	1
262	Thrombolytic Therapy: Current Status. New England Journal of Medicine, 1988, 318, 1512-1520.	13.9	509
263	An Overview of Hemostasis. Veterinary Clinics of North America - Small Animal Practice, 1988, 18, 5-20.	0.5	27
264	Characterization of a Panel of Monoclonal Antibodies Against Human Tissue-Type Plasminogen Activator. Hybridoma, 1988, 7, 177-184.	0.9	5
265	Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.. Arteriosclerosis (Dallas, Tex), 1988, 8, 68-72.	4.9	300
266	Plasminogen Activation: Biochemistry, Physiology, and Therapeutics. Critical Reviews in Biotechnology, 1988, 8, 131-148.	5.1	23
267	Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. Nucleic Acids Research, 1988, 16, 7527-7544.	6.5	24
268	Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.. Journal of Cell Biology, 1988, 106, 971-978.	2.3	160
269	Roles for chloride ion and fibrinogen in the activation of [Glu1]plasminogen in human plasma.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 3595-3598.	3.3	15
270	Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2800-2804.	3.3	239
271	Hormonal Regulation of Tissue-Type Plasminogen Activator Messenger Ribonucleic Acid Levels in Rat Granulosa Cells: Mechanisms of Induction by Follicle-Stimulating Hormone and Gonadotropin Releasing Hormone. Molecular Endocrinology, 1988, 2, 854-861.	3.7	47
272	[26] Plasminogen activators and their inhibitors. Methods in Enzymology, 1988, 163, 293-302.	0.4	32
273	Recognition and Management of Disseminated Intravascular Coagulation in Horses. Veterinary Clinics of North America Equine Practice, 1988, 4, 115-143.	0.3	30
274	Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 985-989.	3.3	72
275	Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. Blood, 1988, 71, 734-741.	0.6	53

#	Article	IF	Citations
276	Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood, 1988, 71, 220-225.	0.6	456
277	Streptokinase Therapy for Occluded Tenckhoff Catheters in Children on CAPO. Peritoneal Dialysis International, 1988, 8, 137-139.	1.1	10
278	Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.. EMBO Journal, 1988, 7, 2731-2740.	3.5	104
279	Low level diode laser treatment for hematomas under grafted skin and its photobiological mechanisms.. Keio Journal of Medicine, 1988, 37, 415-428.	0.5	13
280	Intrathecal Fibrinolytic Therapy after Subarachnoid Hemorrhage: Dosage Study in a Primate Model and Review of the Literature. Canadian Journal of Neurological Sciences, 1989, 16, 28-40.	0.3	53
281	Activation/inactivation of human factor V by plasmin. Blood, 1989, 73, 185-190.	0.6	148
282	PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood, 1989, 73, 1213-1217.	0.6	74
283	Endotoxin-induced production of plasminogen activator inhibitor by human monocytes is autonomous and can be inhibited by lipid X. Blood, 1989, 73, 2188-2195.	0.6	26
284	Plasminogen binding to rat hepatocytes in primary culture and to thin slices of rat liver. Blood, 1989, 74, 729-736.	0.6	48
285	Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes. Blood, 1989, 74, 1635-1643.	0.6	21
286	Tissue-type plasminogen activator mutants. Theoretical and clinical considerations.. Circulation, 1989, 79, 1391-1392.	1.6	12
287	Plasminogen activators. The old and the new.. Circulation, 1989, 79, 217-224.	1.6	42
288	Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.. Journal of Cell Biology, 1989, 108, 1987-1995.	2.3	317
289	Regulation of Tissue Plasminogen Activator Expression. Annual Review of Physiology, 1989, 51, 245-262.	5.6	31
290	Circadian variation of plasma fibrinopeptide A level in patients with variant angina.. Circulation, 1989, 80, 1617-1626.	1.6	116
291	Inhibitors and activators of fibrinolysis during and after childbirth in maternal and cord blood. Journal of Perinatal Medicine, 1989, 17, 113-119.	0.6	14
292	Structural changes in fibrin clot associated with the proteolytic activity induced by tissue type plasminogen activator. An NMR study. BBA - Proteins and Proteomics, 1989, 995, 295-300.	2.1	2
293	Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction. American Journal of Cardiology, 1989, 63, 1025-1031.	0.7	24

#	Article	IF	Citations
294	The action of Russell's viper venom on fibrin formation and fibrinolysis in vivo. British Journal of Haematology, 1989, 71, 107-111.	1.2	9
295	The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to uâ€PA rather than defibrination. British Journal of Haematology, 1989, 71, 511-517.	1.2	114
296	Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. International Journal of Cancer, 1989, 43, 816-822.	2.3	24
297	The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. Journal of Cellular Biochemistry, 1989, 40, 215-227.	1.2	106
298	Urokinase therapy for a central venous catheter thrombus. American Journal of Hematology, 1989, 31, 269-272.	2.0	16
299	Thrombin and plasmin generation in patients with liver disease. American Journal of Hematology, 1989, 32, 30-35.	2.0	42
300	Clinical disorders of fibrinolysis: A critical review. Blut, 1989, 59, 1-14.	1.2	55
301	Antithrombin III activity (residual thrombin activity) in plasma from non-medicated or heparinized horses. Veterinary Research Communications, 1989, 13, 31-46.	0.6	7
302	Plasminogen activation in plasma of patients with systemic lupus erythematosus. Rheumatology International, 1989, 8, 273-277.	1.5	4
303	Cumulative Irritant Dermatitis and Abnormal Epidermal Plasminogen Activator Activity: What Connection?. International Journal of Dermatology, 1989, 28, 550-551.	0.5	0
304	Plasmin-catalysed cleavage of single chain tissue-type plasminogen activator in fibrin clots. Fibrinolysis, 1989, 3, 215-220.	0.5	8
305	Plasminogen activator inhibitor type 2 cDNA transfected into Chinese hamster ovary cells is stably expressed but not secreted. Fibrinolysis, 1989, 3, 189-196.	0.5	15
306	Production and secretion of porcine urokinase in Saccharomyces cerevisiae: characterization of the secreted gene product. Gene, 1989, 85, 545-551.	1.0	11
307	Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis. Gene, 1989, 84, 127-133.	1.0	20
308	Clot uptake of labeled active and inhibited tissue plasminogen activator. Biochimica Et Biophysica Acta - General Subjects, 1989, 991, 62-67.	1.1	1
309	Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis. Thrombosis Research, 1989, 56, 59-65.	0.8	2
310	Oxidized fibrin(ogen) derivatives enhance the activity of tissue type plasminogen activator. Thrombosis Research, 1989, 56, 221-228.	0.8	24
311	Activation of blood coagulation and fibrinolysis in diabetes mellitus: Evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex. Thrombosis Research, 1989, 55, 727-735.	0.8	30

#	Article	IF	Citations
312	Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thrombosis Research, 1989, 54, 41-52.	0.8	47
313	Proton NMR studies of aliphatic ligand binding to human plasminogen kringle 4. Biochemistry, 1989, 28, 1368-1376.	1.2	37
314	Proton NMR structural characterization of a recombinant kringle 2 domain from human tissue-type plasminogen activator. Biochemistry, 1989, 28, 9350-9360.	1.2	28
315	Activation of pro-urokinase by plasmin: Non-michaelian kinetics indicates a mechanism of negative cooperativity. Archives of Biochemistry and Biophysics, 1989, 268, 438-446.	1.4	26
316	Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation. Clinica Chimica Acta, 1989, 183, 323-331.	0.5	18
317	Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. Experimental Eye Research, 1989, 49, 195-203.	1.2	24
318	Plasma plasminogen concentrations in clinically normal horses: the effect of age, sex and pregnancy. Equine Veterinary Journal, 1989, 21, 119-122.	0.9	0
319	Production of proteases type plasminogen activator and their inhibitor in cornea. Biochemical and Biophysical Research Communications, 1989, 160, 1021-1025.	1.0	14
320	Platelet inhibitor agents in cardiovascular disease: An update. Journal of the American College of Cardiology, 1989, 14, 813-836.	1.2	146
322	Plasmin-Î±2-plasmin inhibitor complex and Î±2-plasmin inhibitor in chronic subdural hematoma. Journal of Neurosurgery, 1989, 70, 68-72.	0.9	42
323	Changes in milk plasminogen, plasmin andin vitrobacterial growth in whey during early lactation. Journal of Dairy Research, 1989, 56, 719-725.	0.7	5
324	SYSTEMIC EFFECTS OF TISSUE PLASMINOGEN ACTIVATOR-ASSOCIATED FIBRINOLYSIS AND ITS RELATION TO THROMBIN GENERATION IN ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1989, 47, 978-983.	0.5	184
326	Effects of penicillins and 6-aminohexanoic acid on the kinetics of human plasmin. Biochemical Journal, 1989, 260, 609-612.	1.7	9
327	Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism.. Stroke, 1990, 21, 1663-1667.	1.0	83
328	Variation with season and lactation of plasmin and plasminogen concentrations in Montbeliard cows' milk. Journal of Dairy Research, 1990, 57, 423-435.	0.7	35
329	Localization of tissue plasminogen activator on experimental thrombi in rats.. Journal of Pharmacobio-dynamics, 1990, 13, 751-759.	0.5	4
330	Anistreplase: A Novel Thrombolytic Agent for Acute Myocardial Infarction. DICP: the Annals of Pharmacotherapy, 1990, 24, 607-615.	0.2	1
331	A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease. Chest, 1990, 97, 168S-171S.	0.4	14

#	Article	IF	Citations
332	Antipsoriatic Therapies Inhibit Epidermal Plasminogen Activator Activity. International Journal of Dermatology, 1990, 29, 528-530.	0.5	9
333	A Novel Screening System for Yeast Strains Capable of Secreting Tissue Plasminogen Activator. Nature Biotechnology, 1990, 8, 956-958.	9.4	9
334	Human and murine urokinase cDNAs linked to the murine alphaA-crystallin promoter exhibit lens and non-lens expression in transgenic mice. FEBS Journal, 1990, 190, 31-38.	0.2	33
335	Protease and Plasminogen Activator Activity in Human Bladder Carcinoma. British Journal of Urology, 1990, 66, 170-174.	0.1	6
336	A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombinâ€“antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. British Journal of Haematology, 1990, 74, 471-479.	1.2	64
337	Pharmacologic agents in the management of bleeding disorders. Transfusion, 1990, 30, 541-551.	0.8	38
338	6 Mechanism of action of the thrombolytic agents. Best Practice and Research: Clinical Haematology, 1990, 3, 583-599.	1.1	11
339	Future directions in plasminogen activator therapy. Clinical Cardiology, 1990, 13, 375-381.	0.7	11
340	The potency of tissue-type plasminogen activator (TPA) determined with chromogen and clot-lysis assays. Biologicals, 1990, 18, 103-111.	0.5	10
341	Plasminogen activation at the cell surface-matrix interface. Cell Differentiation and Development, 1990, 32, 255-262.	0.4	41
342	Use of plasminogen activators in venous thrombosis. World Journal of Surgery, 1990, 14, 688-693.	0.8	5
343	Effects of tumor necrosis factor Î± and Î² on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis and Rheumatism, 1990, 33, 542-552.	6.7	102
344	Thrombin Vs. Plasmin generation in disseminated Intravascular coagulation associated with various underlying disorders. American Journal of Hematology, 1990, 33, 90-95.	2.0	96
345	Regulation of Tissue Plasminogen Activator in Sickle Cell Anemia. American Journal of Hematology, 1990, 35, 167-170.	2.0	10
346	Thrombolytic Agents: Balancing Cost, Efficacy, and Side Effects. Clinical Cardiology, 1990, 13, VI-37.	0.7	3
347	Effects of therapeutic doses of heparin on thrombolysis with tissue- type plasminogen activator in rabbits. Blood, 1990, 76, 2030-2036.	0.6	17
348	Decreased fibrinolytic activity in juvenile chronic arthritis.. Annals of the Rheumatic Diseases, 1990, 49, 973-975.	0.5	7
349	Rationale for Bolus t-PA Therapy To Improve Efficacy and Safety. Chest, 1990, 97, 161S-167S.	0.4	50

#	Article	IF	Citations
350	Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. Biochemistry, 1990, 29, 5906-5911.	1.2	50
351	Secretion of active kringle-2-serine protease in Escherichia coli. Biochemistry, 1990, 29, 9737-9745.	1.2	29
352	Construction, expression and biochemical characterisation of a novel triskringle plasminogen activator gene. Fibrinolysis, 1990, 4, 79-86.	0.5	5
353	Efficacy and selectivity of tissue-type and urokinase-type plasminogen activators in a humanised pulmonary embolism model. Fibrinolysis, 1990, 4, 87-94.	0.5	3
354	Expression and characterisation of finger protease (FP); a mutant tissue-type plasminogen activator (t-PA) with improved pharmacokinetics. Fibrinolysis, 1990, 4, 131-140.	0.5	6
355	Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells. Molecular and Cellular Endocrinology, 1990, 72, 103-110.	1.6	10
356	The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis. Annals of the New York Academy of Sciences, 1990, 598, 238-247.	1.8	29
357	Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. Journal of Pediatrics, 1990, 116, 798-801.	0.9	77
358	Regulation and Control of the Fibrinolytic System. , 1990, , 9-20.		2
359	t-PA Activity elicited by venous occlusion or DDAVP infusion does not produce plasmin activity in normal subjects. Thrombosis Research, 1990, 59, 1007-1011.	0.8	1
360	Single chain - urokinase binds to oxidized fibrin(ogen) derivatives. Thrombosis Research, 1990, 59, 351-361.	0.8	5
361	Purification and characterization of a plasma factor which cleaves single-chain form of t-PA and u-PA. Thrombosis Research, 1990, 57, 27-43.	0.8	5
362	New developments in thrombolytic therapy. Thrombosis Research, 1990, 57, 105-131.	0.8	27
363	The receptor for human urokinase: a potential target for anti-invasive and anti-metastatic therapy. Thrombosis Research, 1990, 57, 49-60.	0.8	4
364	Conformational differences between latent and active plasminogen activator inhibitor, PAI-1: A spectroscopic study. Thrombosis Research, 1990, 59, 851-858.	0.8	13
365	Production of plasminogen activator and plasminogen activator inhibitor by bovine lymphatic endothelial cells: Modulation by TNF-Î±. Thrombosis Research, 1990, 59, 567-579.	0.8	15
366	Specificity of functional determination of urokinase in human plasma using selective oxidants. Fibrinolysis, 1990, 4, 148-149.	0.5	2
367	Plasminogen activator inhibitors: hormonally regulated serpins. Molecular and Cellular Endocrinology, 1990, 68, 1-19.	1.6	406

#	Article	IF	Citations
368	Antithrombin III activity in horses with colic: an analysis of 46 cases. Equine Veterinary Journal, 1991, 23, 211-214.	0.9	35
369	Releasable tissue plasminogen activators in ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 1991, 1, 203-208.	0.7	0
370	Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator. Fibrinolysis, 1991, 5, 207-215.	0.5	30
371	Effect of Coagulants, Somatic Cell Enzymes, and Extracellular Bacterial Enzymes on Plasminogen Activation. Journal of Dairy Science, 1991, 74, 772-782.	1.4	34
372	The role of the endothelium in in vivo anticoagulation. Journal of Oral and Maxillofacial Surgery, 1991, 49, 507-511.	0.5	5
373	Tissue plasminogen activator for gangrene in fulminant meningococcaemia. Lancet, The, 1991, 337, 1359.	6.3	19
374	The contribution of fibrinolysis to postbypass bleeding. Journal of Cardiothoracic and Vascular Anesthesia, 1991, 5, 13-17.	0.6	42
375	The effect of change in the rhythm of food intake and sleeping time during ramadan on the diurnal variation of fibrinolytic activity. Fibrinolysis, 1991, 5, 177-180.	0.5	3
376	Basal expression and insulin-mediated induction of PAI-1 mRNA in Hep G2 cells. Fibrinolysis, 1991, 5, 81-86.	0.5	16
377	Silent myocardial ischaemia episodes in non-insulin dependent diabetes mellitus: relationship with haemostatic alterations. Fibrinolysis, 1991, 5, 121-125.	0.5	0
378	Partial Purification and Characterization of Native Plasminogen Activators from Bovine Milk. Journal of Dairy Science, 1991, 74, 2060-2072.	1.4	23
379	Substrate specificity of tissue-type and urokinase-type plasminogen activators. Biochemical and Biophysical Research Communications, 1991, 174, 432-438.	1.0	21
380	Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug. Journal of Molecular Biology, 1991, 222, 1035-1051.	2.0	59
381	Coagulopathy and haemorrhage in human victims of Bothrops jararaca envenoming in Brazil. Toxicon, 1991, 29, 961-972.	0.8	87
382	Use of the urokinase-type plasminogen activator gene as a general tool to monitor expression in transgenic animals: study of the tissue-specificity of the murine whey acidic protein (WAP) expression signals. Journal of Biotechnology, 1991, 20, 201-212.	1.9	12
383	Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Thrombosis Research, 1991, 64, 677-689.	0.8	23
384	Effect of oxidants on proteases of the fibrinolytic system: Possible role for methionine residues in the interaction between tissue type plasminogen activator and fibrin. Thrombosis Research, 1991, 61, 191-200.	0.8	11
385	Participation of phospholipase A2 in induction of tissue plasminogen activator(t-PA) production by human fibroblast, IMR-90 cells, stimulated by proteose peptone. Thrombosis Research, 1991, 64, 191-202.	0.8	5

#	Article	IF	Citations
386	The use of high dose aprotinin in liver transplantation: The influence on fibrinolysis and blood loss. Thrombosis Research, 1991, 63, 287-297.	0.8	82
387	Recombinant Tissue-Type Plasminogen Activator. , 1991, 19, 197-223.		1
388	Enhancement of the fibrinolytic activity of sheep endothelial cells by retroviral vector-mediated gene transfer. Blood, 1991, 77, 533-541.	0.6	61
389	Basic and clinical aspects of fibrinolysis and thrombolysis. Blood, 1991, 78, 3114-3124.	0.6	623
390	Pulmonary Embolism in the Elderly. Cardiology Clinics, 1991, 9, 457-474.	0.9	17
391	Directed Plasminogen Activation at the Surface of Normal and Malignant Cells. Advances in Cancer Research, 1991, 57, 273-328.	1.9	254
393	The Fibrinolytic System in Diabetes Mellitus. Diabetic Medicine, 1991, 8, 898-905.	1.2	54
394	Contrasting Fibrinolytic Responses in Type 1 (Insulinâ€dependent) and Type 2 (Nonâ€insulinâ€dependent) Diabetes. Diabetic Medicine, 1991, 8, 954-959.	1.2	46
395	Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. Biochemical Journal, 1991, 274, 491-496.	1.7	16
396	Structural requirements of position A Î±-157 in fibrinogen for the fibrin-induced rate enhancement of the activation of plasminogen by tissue-type plasminogen activator. Biochemical Journal, 1991, 276, 655-659.	1.7	25
397	Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. Biochemical Journal, 1991, 276, 785-791.	1.7	33
398	Localization of tissue plasminogen activator on experimental microthrombi in rats. Microautoradiographic observations.. Journal of Pharmacobio-dynamics, 1991, 14, 25-33.	0.5	4
399	Thrombolytic Effect of Tissue Plasminogen Activator in a Cerebral Embolic Model.. Journal of Pharmacobio-dynamics, 1991, 14, 399-406.	0.5	1
400	Tissue plasminogen activator (A review). Indian Journal of Clinical Biochemistry, 1991, 6, 1-8.	0.9	0
401	Close similarity between cultured human omental mesothelial cells and endothelial cells in cytochemical markers and plasminogen activator production. In Vitro Cellular & Developmental Biology, 1991, 27, 542-548.	1.0	24
402	Thrombosis, fibrinolysis, and thrombolytic therapy: A perspective. Progress in Cardiovascular Diseases, 1991, 34, 89-100.	1.6	7
403	Pacingâ€induced myocardial ischemia does not affect the endothelial release of coagulant and fibrinolytic factors into the coronary circulation. Clinical Cardiology, 1991, 14, 250-256.	0.7	6
404	TOWARDS THE DEVELOPMENT OF IMPKOVED THROMBOLYTIC AGENTS. British Journal of Haematology, 1991, 77, 261-266.	1.2	8

#	Article	IF	Citations
405	Plasmin generation and fibrin(ogen)olysis following desmopressin infusion. American Journal of Hematology, 1991, 36, 255-258.	2.0	11
406	Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: Correlation with CEA distribution and tumor cell kinetics. Journal of Surgical Oncology, 1991, 46, 246-256.	0.8	5
407	Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis. International Ophthalmology, 1991, 15, 79-86.	0.6	6
408	Biological significance of tissue plasminogen activator content in brain tumors. Journal of Neurosurgery, 1991, 74, 480-486.	0.9	52
409	Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris. Does lipoprotein(a) alter fibrinolysis?. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 1772-1777.	3.8	35
410	Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.. Journal of Cell Biology, 1991, 115, 1773-1781.	2.3	78
411	The Inhibitor Reacting with a Tumour Cell Surface Protease can be Exchanged With Plasminogen Activator Inhibitor (PAI-1). Journal of Enzyme Inhibition and Medicinal Chemistry, 1991, 4, 273-279.	0.5	2
412	Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.. Circulation, 1991, 84, 287-292.	1.6	38
413	Regulation of Type One Plasminogen Activator Inhibitor Gene Expression in Cultured Endothelial Cells and the Vessel Wall. , 1991, , 187-208.		2
415	Regulation of Human Tissue-Type Plasminogen Activator Gene Transcription by Epidermal Growth Factor and 3â€²,5â€²-Cyclic Adenosine Monophosphate. Molecular Endocrinology, 1991, 5, 1773-1779.	3.7	20
416	Optimal control of plasmin production by Streptokinase input: Towards optimal therapy in acute myocardial infarction. , 1992, , .		1
417	Pharmacology of Fibrinolysis. Chest, 1992, 101, 91S-97S.	0.4	16
418	Lung Capillary Endothelial Cells Produce and Secrete Urokinase-type Plasminogen Activator. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 90-94.	1.4	17
419	Drugs affecting blood coagulation and hemostasis. Side Effects of Drugs Annual, 1992, , 410-416.	0.6	1
420	Effects of Prolactin on Ovarian Plasmin Generation in the Process of Ovulation. Biology of Reproduction, 1992, 46, 322-327.	1.2	17
421	Cultured rat aortic vascular smooth muscle cells digest naturally produced extracellular matrix. Involvement of plasminogen-dependent and plasminogen-independent pathways.. Circulation Research, 1992, 71, 385-392.	2.0	60
422	New Developments in Thrombolytic Therapy. Advances in Pharmacology, 1992, 23, 227-262.	1.2	1
423	Stimulation of plasmin activity by oleic acid. Biochemical Journal, 1992, 282, 863-866.	1.7	29

#	Article	IF	Citations
424	Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA. Biochemical Journal, 1992, 284, 545-550.	1.7	28
425	Bolus Thrombolysis in Venous Thromboembolism. Chest, 1992, 101, 172S-182S.	0.4	25
426	Cell-free synthesis of enzymically active tissue-type plasminogen activator. Protein folding determines the extent of N-linked glycosylation. Biochemical Journal, 1992, 286, 275-280.	1.7	65
427	Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.. Circulation, 1992, 86, 1241-1248.	1.6	108
428	S-nitrosylation of tissue-type plasminogen activator confers vasodilatory and antiplatelet properties on the enzyme.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8087-8091.	3.3	170
429	Conformation ability test of human, rabbit and bovine plasminogens and their specific interaction with streptokinase. International Journal of Biological Macromolecules, 1992, 14, 229-234.	3.6	3
430	Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation. Thrombosis Research, 1992, 68, 57-65.	0.8	23
431	Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma. Thrombosis Research, 1992, 65, 449-456.	0.8	15
432	Fibrin-specific Fibrinolysis. Annals of the New York Academy of Sciences, 1992, 667, 259-271.	1.8	29
433	Remaining Perspectives of Mutant and Chimeric Plasminogen Activators. Annals of the New York Academy of Sciences, 1992, 667, 357-364.	1.8	4
434	Possible roles of arachidonic acid and its metabolites in induction of tissue plasminogen activator (t-PA) production in human fibroblast, IMR-90 cells by proteose peptone. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1133, 167-171.	1.9	3
435	Effect of aspirin on plasminogen activator release in perfused rat hindlegs. Fibrinolysis, 1992, 6, 63-68.	0.5	3
436	Purification and characterisation of recombinant rabbit plasminogen activator inhibitor-1 expressed in Saccharomyces cerevisiae. Fibrinolysis, 1992, 6, 263-272.	0.5	15
437	A plasminogen-related gene is expressed in cancer cells. Biochemical and Biophysical Research Communications, 1992, 186, 1108-1114.	1.0	28
438	Successful use of low-dose tissue plasminogen activator for treatment of thrombosed prosthetic valve in a 22-month-old child. American Heart Journal, 1992, 124, 783-785.	1.2	14
439	Analysis of plasmin binding and urokinase activation of plasminogen bound to the heymann nephritis autoantigen, gp330. Archives of Biochemistry and Biophysics, 1992, 299, 255-260.	1.4	12
440	Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: A key event in melanoma cell invasiveness in vitro. Experimental Cell Research, 1992, 199, 179-190.	1.2	52
441	Production and secretion of plasminogen in cultured rat brain microglia. FEBS Letters, 1992, 308, 179-182.	1.3	91

#	Article	IF	Citations
442	â€œBrain Attackâ€: An Indication for Thrombolysis?. Annals of Pharmacotherapy, 1992, 26, 73-80.	0.9	8
443	Thrombolytic Therapy in Arterial Disease. I: Available Agents. Vascular Medicine Review, 1992, vmr-3, 146-155.	0.2	0
444	Characterization of urokinase receptor expression by human placental trophoblasts. Blood, 1992, 79, 2917-2929.	0.6	91
445	Urokinase Plasminogen Activator Is Immunocytochemically Detectable in Squamous Cell but Not Basal Cell Carcinomas. Journal of Investigative Dermatology, 1992, 98, 351-358.	0.3	18
446	Plasminogen binding sites in normal human skin. British Journal of Dermatology, 1992, 126, 35-41.	1.4	36
447	Radioiodination of the active site of tissue plasminogen activator: A method for radiolabeling serine proteases with tyrosylprolylarginyl chloromethyl ketone. Analytical Biochemistry, 1992, 206, 73-83.	1.1	11
448	Adsorption of plasminogen from plasma to lysine-derivatized Polyurethane surfaces. Biomaterials, 1992, 13, 1103-1108.	5.7	32
449	Fibrinolytic parameters and hemostatic monitoring: Identifying and predicting patients at risk for major hemorrhagic events. American Journal of Cardiology, 1992, 69, A52-A59.	0.7	11
450	On the molecular interactions between plasminogen-staphylokinase, Î±2-antiplasmin-formula› and fibrin. BBA - Proteins and Proteomics, 1992, 1118, 144-148.	2.1	49
451	LOCALIZATION OF COMPONENTS FROM THE PLASMINOGEN ACTIVATION SYSTEM IN MAMMALIAN TISSUES. Apmis, 1992, 100, 5-27.	0.9	10
452	Spectrophotometric method to quantify and discriminate urokinase and tissue-type plasminogen activators. Analytical Biochemistry, 1992, 200, 156-162.	1.1	8
453	Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue-type plasminogen activator. Hepatology, 1992, 16, 54-59.	3.6	36
454	Effects of linoleic and oleic acid anilides on prostacyclin synthesis and fibrinolytic profile of human endothelial cells in culture: relevance to the toxic oil syndrome. Toxicology, 1993, 81, 181-194.	2.0	5
455	Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann. Archives of Dermatological Research, 1993, 284, 432-439.	1.1	20
456	Exotoxin-induced consumptive coagulopathy in Atlantic salmon, Salmo salar L.: inhibitory effects of exogenous antithrombin and alpha2-macroglobulin on Aeromonas salmonicida serine protease. Journal of Fish Diseases, 1993, 16, 425-435.	0.9	36
457	Plasma protein levels as potential marker traits for resistance to furunculosis. Journal of Fish Diseases, 1993, 16, 561-568.	0.9	37
458	Urokinase-type plasminogen activator in human eccrine sweat. British Journal of Dermatology, 1993, 128, 178-183.	1.4	6
459	Microglia-Derived Elastase Produces a Low-Molecular-Weight Plasminogen that Enhances Neurite Outgrowth in Rat Neocortical Explant Cultures. Journal of Neurochemistry, 1993, 61, 2155-2163.	2.1	39

#	Article	IF	Citations
460	Activation of bovine plasminogen by Streptococcus uberis. FEMS Microbiology Letters, 1993, 114, 67-71.	0.7	49
461	Interaction of staphylokinase with different molecular forms of plasminogen. FEBS Journal, 1993, 211, 91-97.	0.2	27
462	Potassium ion enhances tissue-type plasminogen activator expression in cultured HEL cells. Journal of Bioscience and Bioengineering, 1993, 76, 111-116.	0.9	2
463	Control of clot lysis by gene transfer. Trends in Cardiovascular Medicine, 1993, 3, 61-66.	2.3	8
464	The effect of different exercise intensities on the fibrinolytic system. European Journal of Applied Physiology and Occupational Physiology, 1993, 67, 298-304.	1.2	44
465	Plasminogen-binding protein associated with the plasma membrane of cultured embryonic rat neocortical neurons. FEBS Letters, 1993, 333, 223-228.	1.3	13
466	Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. British Journal of Dermatology, 1993, 128, 612-618.	1.4	32
467	Development of thrombolytic agents. Biotechnology Advances, 1993, 11, 115-130.	6.0	5
468	Functional roles of microglia in the brain. Neuroscience Research, 1993, 17, 187-203.	1.0	196
469	Assays for Native Plasminogen Activators in Bovine Milk. Journal of Dairy Science, 1993, 76, 3362-3368.	1.4	17
470	Neutralization of plasminogen activator inhibitor-1 (PAI-1) by activated protein C is species-dependent. Fibrinolysis, 1993, 7, 123-133.	0.5	3
471	Does a negative D-dimer exclude thrombosis?. Fibrinolysis, 1993, 7, 32-35.	0.5	7
472	The role of 152Val of the fibrinogen AÎ±-chain in the fibrin-induced rate enhancement of the plasminogen activation by t-PA. Fibrinolysis, 1993, 7, 63-67.	0.5	5
473	Complex formation between protein c inhibitor and tissue plasminogen activator during thrombolytic therapy. Fibrinolysis, 1993, 7, 308-315.	0.5	6
474	Increased plasma plasminogen activator inhibitor activity after coronary spasm. International Journal of Cardiology, 1993, 41, 21-29.	0.8	17
475	Plasminogen promotes the development of rat mesencephalic dopaminergic neurons in vitro. Developmental Brain Research, 1993, 75, 31-37.	2.1	43
476	Introduction. Methods in Enzymology, 1993, 223, 1-9.	0.4	7
477	Factors contributing to increased vascular fibrinolytic activity in mongrel dogs.. Circulation, 1993, 87, 1990-2000.	1.6	46

#	Article	IF	Citations
478	Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.. Heart, 1993, 70, 382-385.	1.2	66
479	New Insights into the Pathogenesis of Coagulation Dysfunction in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 1993, 11, 27-36.	0.6	59
480	Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.. Circulation, 1993, 87, 659-675.	1.6	224
482	Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties. Blood, 1993, 81, 1312-1322.	0.6	21
483	One-step competitive immunochromatographic assay for semiquantitative determination of lipoprotein(a) in plasma. Clinical Chemistry, 1993, 39, 619-624.	1.5	82
484	Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery, 1993, 106, 339-345.	0.4	17
485	Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients. An immunocytochemical study.. Circulation, 1994, 89, 1599-1608.	1.6	47
486	Prolactin Inhibits Ovulation by Reducing Ovarian Plasmin Generation. Biology of Reproduction, 1994, 50, 1223-1230.	1.2	15
487	Enhancement of fibrinolytic activity of human plasma in the presence of acetone. Scandinavian Journal of Clinical and Laboratory Investigation, 1994, 54, 353-359.	0.6	0
488	Hematologic Emergencies. Veterinary Clinics of North America - Small Animal Practice, 1994, 24, 1139-1172.	0.5	5
489	Extracellular Matrixâ€Degrading Proteinases in the Nervous System. Brain Pathology, 1994, 4, 145-156.	2.1	194
490	Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.. Circulation, 1994, 89, 2715-2721.	1.6	88
491	Inhibition of neutrophil activation by fibrinogen. Inflammation, 1994, 18, 525-535.	1.7	20
492	Thrombolysis in thromboembolic diseases. Annals of Hematology, 1994, 69, S41-S57.	0.8	5
493	Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. Journal of Neuro-Oncology, 1994, 22, 139-151.	1.4	34
494	Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 1994, 73, 1398-1405.	2.0	64
495	Inhibition of tissue plasminogen activators and urokinase by human saliva. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 77, 356-361.	0.6	3
496	Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney International, 1994, 45, 43-47.	2.6	18

#	Article	IF	Citations
497	8 Fibrinolysis and thrombosis. Best Practice and Research: Clinical Haematology, 1994, 7, 559-572.	1.1	18
498	Purification and Characterization of Active and Stable Recombinant Plasminogen-Activator Inhibitor Accumulated at High Levels in Escherichia coli. FEBS Journal, 1994, 224, 125-134.	0.2	65
499	Mechanisms of plasminogen activation. Journal of Internal Medicine, 1994, 236, 415-424.	2.7	54
500	The pathophysiology of venous thrombosis. Progress in Cardiovascular Diseases, 1994, 36, 439-446.	1.6	17
501	Effects of labor and delivery on fibrinolysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1994, 55, 163-168.	0.5	18
502	Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1221, 307-314.	1.9	25
503	Free-flow electrophoresis as a preparative separation technique. Analytical Chemistry, 1994, 66, 86A-94A.	3.2	93
504	Localization of urokinase- and tissue-type plasminogen activator mRNAs in rat testes. Molecular and Cellular Endocrinology, 1994, 105, 55-64.	1.6	24
505	Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases plasma fibrinolytic activity in vivo. Fibrinolysis, 1994, 8, 42-47.	0.5	2
506	Lys-and Glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. Thrombosis Research, 1994, 74, 555-563.	0.8	18
507	Role of platelet GPIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitors type-1 (PAI-1) release. Life Sciences, 1994, 54, 1155-1162.	2.0	10
508	Administration of high-dose aprotinin during nonprimary cardiovascular surgery: Case reports and review of the literature. Journal of Clinical Anesthesia, 1994, 6, 515-520.	0.7	1
509	Heparin and heparan sulfate enhancement of the inhibitory activity of plasminogen activator inhibitor type 1 toward urokinase type plasminogen activator. Biochimica Et Biophysica Acta - General Subjects, 1994, 1201, 217-222.	1.1	6
510	Capturing host plasmin(ogen): a common mechanism for invasive pathogens?. Trends in Microbiology, 1994, 2, 20-24.	3.5	175
511	Physiological Changes Due to Age. Drugs and Aging, 1994, 5, 20-33.	1.3	26
512	Regulation of fibrinolysis by non-esterified fatty acids. Biochemical Journal, 1994, 300, 251-255.	1.7	24
513	Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. Journal of Leukocyte Biology, 1994, 56, 110-116.	1.5	10
514	Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.. Stroke, 1994, 25, 451-456.	1.0	20

#	Article	IF	Citations
515	Thrombosis and the Pharmacology of Antithrombotic Agents. Annals of Pharmacotherapy, 1995, 29, 892-905.	0.9	41
516	Expression of Tissue Plasminogen Activator in Cerebral Capillaries. Neurosurgery, 1995, 37, 955-960.	0.6	58
517	Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis, 1995, 9, 263-276.	0.5	143
518	Amniotic fluid plasminogen activators and inhibitors and TAT-complex levels during 2nd trimester pregnancy and labour. Fibrinolysis, 1995, 9, 121-126.	0.5	18
519	1 Mechanisms of physiological fibrinolysis. Best Practice and Research: Clinical Haematology, 1995, 8, 277-290.	1.1	150
520	The Role of an Enolase-Related Molecule in Plasminogen Binding to Cells. FEBS Journal, 1995, 227, 407-415.	0.2	222
521	Gerinnungshemmende Wirkstoffe blutsaugender Tiere: von Hirudin zu Hirudinmimetica. Angewandte Chemie, 1995, 107, 948-962.	1.6	3
522	Anticoagulatory Substances of Bloodsucking Animals: From Hirudin to Hirudin Mimetics. Angewandte Chemie International Edition in English, 1995, 34, 867-880.	4.4	17
523	N-glycosylation site mapping of recombinant tissue plasminogen activator by micellar electrokinetic capillary chromatography. Biomedical Chromatography, 1995, 9, 59-67.	0.8	16
524	Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 1995, 1, 145-151.	1.0	4
525	Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis. Pediatric Nephrology, 1995, 9, 104-111.	0.9	62
526	Evidence of ongoing coagulation and fibrinolysis in early-maturing Atlantic salmon, Salmo salar L.. Journal of Fish Diseases, 1995, 18, 623-626.	0.9	3
527	Differential Cytokine Regulation of PAI-1 Gene Expression Between Human Umbilical and Subcutaneous Fat-Derived Microvascular Endothelial Cells. Endothelium: Journal of Endothelial Cell Research, 1995, 3, 243-252.	1.7	1
528	The Activation-resistant Conformation of Recombinant Human Plasminogen Is Stabilized by Basic Residues in the Amino-terminal Hinge Region. Journal of Biological Chemistry, 1995, 270, 15770-15776.	1.6	41
529	The Significance of Fibrin Binding by Plasminogen Activator Inhibitor 1 for the Mechanism of Tissue-type Plasminogen Activator-mediated Fibrinolysis. Journal of Biological Chemistry, 1995, 270, 11205-11208.	1.6	17
530	The Role of the Lysyl Binding Site of Tissue-type Plasminogen Activator in the Interaction with a Forming Fibrin Clot. Journal of Biological Chemistry, 1995, 270, 12355-12360.	1.6	17
531	Streptokinase-mediated plasminogen activation using a recombinant dual fusion protein construct. A novel approach to study bacterial-host protein interactions. Journal of Microbiological Methods, 1995, 23, 261-280.	0.7	4
532	Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon, 1995, 33, 1605-1617.	0.8	28

#	Article	IF	Citations
533	Effect of fucoidan during activation of human plasminogen. Thrombosis Research, 1995, 79, 237-247.	0.8	22
534	The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones. American Journal of Obstetrics and Gynecology, 1995, 173, 801-808.	0.7	29
535	A mathematical model of plasminogen activation and fibrinogenolysis during thrombolytic therapy with t-PA. , 0, , .		0
536	The appearance of active plasminogen activator of urokinase type (u-PA) in the rabbit anterior eye segment irradiated by UVB rays. A histochemical and biochemical study. Acta Histochemica, 1995, 97, 257-262.	0.9	14
537	Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. Microbial Pathogenesis, 1995, 18, 153-166.	1.3	52
538	Cell Surface-Bound Urokinase-Type Plasminogen Activator Facilitates Infiltration of Freshly Isolated Granulocytes into a Fibrin Matrix. Immunobiology, 1995, 194, 363-375.	0.8	8
539	Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding. Journal of Vascular and Interventional Radiology, 1995, 6, 19S-23S.	0.2	24
540	Immunogenicity of Tissue Plasminogen Activators in Rhesus Monkeys: Antibody Formation and Effects on Blood Level and Enzymatic Activity. Fundamental and Applied Toxicology, 1996, 30, 243-254.	1.9	16
541	Alterations of Fibrinolytic Activity in Human During and After Hyperbaric Oxygen Exposure.. Applied Human Science: Journal of Physiological Anthropology, 1996, 15, 239-242.	0.2	7
542	The future of thrombolysis in the treatment of acute myocardial infarction. European Heart Journal, 1996, 17, 55-60.	1.0	47
543	Prevention of Microvascular Thrombosis with Short-Term Infusion of Human Tissue-Type Plasminogen Activator. Plastic and Reconstructive Surgery, 1996, 98, 118-128.	0.7	35
544	Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography. BBA - Proteins and Proteomics, 1996, 1295, 103-109.	2.1	18
545	Possible involvement of plasmin in long-term potentiation of rat hippocampal slices. Brain Research, 1996, 739, 276-281.	1.1	39
546	Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI). Fibrinolysis, 1996, 10, 13-16.	0.5	22
547	The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. BBA - Proteins and Proteomics, 1996, 1298, 199-208.	2.1	17
548	Effects of fibrin and Î±2-antiplasmin on plasminogen activation by staphylokinase. , 1996, 53, 151-157.		15
549	Blood coagulation profile of the Asian elephant (Elephas maximus). Zoo Biology, 1996, 15, 413-423.	0.5	17
550	Purpuras and related conditions. Journal of the European Academy of Dermatology and Venereology, 1996, 7, 1-25.	1.3	22

#	Article	IF	Citations
551	CUTANEOUS NECROTIZING VASCULITIS. International Journal of Dermatology, 1996, 35, 457-474.	0.5	39
553	Rearrangements of the Fibrin Network and Spatial Distribution of Fibrinolytic Components during Plasma Clot Lysis. Journal of Biological Chemistry, 1996, 271, 2133-2138.	1.6	92
554	Molecular and Functional Characterization of the Urokinase Receptor on Human Mast Cells. Journal of Biological Chemistry, 1997, 272, 7824-7832.	1.6	61
555	Identification of a Hydrophobic Exosite on Tissue Type Plasminogen Activator That Modulates Specificity for Plasminogen. Journal of Biological Chemistry, 1997, 272, 1811-1816.	1.6	20
556	Staphylokinase Requires NH2-terminal Proteolysis for Plasminogen Activation. Journal of Biological Chemistry, 1997, 272, 6067-6072.	1.6	47
557	Antithrombotic, procoagulant, and fibrinolytic mechanisms in cerebral circulation: implications for brain injury and protection. Neurosurgical Focus, 1997, 2, E7.	1.0	14
558	Trends and Future Developments in the Pharmacological Treatment of Acute Ischaemic Stroke. Drugs, 1997, 54, 9-38.	4.9	60
559	Thrombolytic Therapy in the Treatment of Stroke. Drugs, 1997, 54, 90-99.	4.9	26
560	A novel approach to explore the role of plasminogen in bacterial pathogenesis. Trends in Microbiology, 1997, 5, 466-467.	3.5	25
561	The role of the vascular endothelium in inflammatory syndromes, atherogenesis, and the propagation of disease. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 11, 316-321.	0.6	31
562	Effect of sodium ozagrel on platelet rich plasma clot lysis. Pathophysiology, 1997, 4, 169-174.	1.0	0
563	Detergent tween 80 modifies the specific activity of PAI-1. Fibrinolysis and Proteolysis, 1997, 11, 165-170.	1.1	12
564	Rationale for the bolus administration of fibrin-specific thrombolytic agents. Fibrinolysis and Proteolysis, 1997, 11, 23-27.	1.1	3
565	Endothelial Function, Fibrinolysis, and Angiotensinâ€Converting Enzyme Inhibition. Clinical Cardiology, 1997, 20, II-34.	0.7	6
566	A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 Domain. Journal of Biological Chemistry, 1997, 272, 2183-2191.	1.6	59
567	Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein). Journal of Biological Chemistry, 1997, 272, 2176-2182.	1.6	30
568	Anesthesia and surgery influences regional net release and uptake rates of tissueâ€type plasminogen activator. An experimental study in the intact pig. Acta Anaesthesiologica Scandinavica, 1997, 41, 151-153.	0.7	1
569	Chronic Nicotine Treatment Enhances Focal Ischemic Brain Injury and Depletes Free Pool of Brain Microvascular Tissue Plasminogen Activator in Rats. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 136-146.	2.4	109

#	Article	IF	Citations
570	Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. British Journal of Cancer, 1997, 75, 388-395.	2.9	198
571	The Plasma Carboxypeptidases and the Regulation of the Plasminogen System. Trends in Cardiovascular Medicine, 1997, 7, 71-75.	2.3	28
572	Characterisation of the Rat Tissue-Type Plasminogen Activator Gene Promoter. Identification of a TAAT-Containing Promoter Element. FEBS Journal, 1997, 248, 676-683.	0.2	12
573	Coagulation and fibrinolytic systems in the ill preterm newborn. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 1100-1104.	0.7	40
574	Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Progress in Cardiovascular Diseases, 1997, 40, 205-238.	1.6	22
575	Postsynaptic blockade of inhibitory postsynaptic currents by plasmin in CA1 pyramidal cells of rat hippocampus. Brain Research, 1997, 761, 93-96.	1.1	13
576	The urokinase-type plasminogen activator system in cancer metastasis: A review. International Journal of Cancer, 1997, 72, 1-22.	2.3	1,493
577	The appearance and possible role of plasminogen activator of urokinase type (u-PA) activity in the cornea related to soft contact lens wear in rabbits. Documenta Ophthalmologica, 1998, 95, 165-179.	1.0	3
578	Hyperthermic Fibrinolysis with rt-PA: In Vitro Results. CardioVascular and Interventional Radiology, 1998, 21, 142-145.	0.9	23
579	Expression of human PAI-2 in the baculovirus expression system. Journal of Industrial Microbiology and Biotechnology, 1998, 21, 175-177.	1.4	1
580	Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. American Journal of Obstetrics and Gynecology, 1998, 179, 520-526.	0.7	77
581	Tyrosine kinase mediated regulation of PAI-1 production in HEL299 fibroblasts and HepG2 hepatoma cells. Fibrinolysis and Proteolysis, 1998, 12, 165-172.	1.1	0
582	Thrombolytic agents â€" an updated overview. Fibrinolysis and Proteolysis, 1998, 12, 39-58.	1.1	19
583	Hyperfibrinolytic activity after head injury is induced by elevated tPA activity. Fibrinolysis and Proteolysis, 1998, 12, 113-118.	1.1	3
584	Cutaneous small-vessel vasculitis. Journal of the American Academy of Dermatology, 1998, 39, 667-690.	0.6	199
585	Saving the zone of stasis in burns with recombinant tissue-type plasminogen activator (r-tPA): an experimental study in rats. Burns, 1998, 24, 217-223.	1.1	35
586	Augmented Pulse-Spray Thrombolysis with tPA by Early Pulsed Intrathrombic Plasminogen Enrichment. Journal of Vascular and Interventional Radiology, 1998, 9, 618-625.	0.2	6
587	Thrombolytic Therapy: A Review of Its Use in Acute Myocardial Infarction. Annals of Pharmacotherapy, 1998, 32, 769-784.	0.9	12

#	Article	IF	Citations
588	Chronic pulmonary hypertensionâ€the monocrotaline model and involvement of the hemostatic system. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 1998, 1, 271-346.	2.9	93
589	Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene. Biochemical and Biophysical Research Communications, 1998, 247, 580-586.	1.0	48
590	Molekularbiologische Charakterisierung des Pankreaskarzinoms. Visceral Medicine, 1998, 14, 14-21.	0.5	0
591	Immunohistochemical Localization of Tissue Plasminogen Activator in Vascular Endothelium of Stroke-prone Regions of the Rat Brain. Neurosurgery, 1998, 43, 909-913.	0.6	27
592	Hereditary Angioneurotic Edema and Thromboembolic Diseases: I: How Symptoms of Acute Attacks Change with Aging.. Internal Medicine, 1998, 37, 440-443.	0.3	7
593	Plasma TAFI Levels Influence the Clot Lysis Time in Healthy Individuals in the Presence of an Intact Intrinsic Pathway of Coagulation. Thrombosis and Haemostasis, 1998, 80, 829-835.	1.8	212
594	Rapid Detection of D-dimer Using a Fiber Optic Biosensor. Thrombosis and Haemostasis, 1998, 79, 94-98.	1.8	26
595	Fibrinolytic Activity of Subretinal Fluid after Cryopexy. European Journal of Ophthalmology, 1999, 9, 291-296.	0.7	5
596	The Plasminogen (Fibrinolytic) System. Thrombosis and Haemostasis, 1999, 82, 259-270.	1.8	352
597	Mechanism of Action of Plasminogen Activators. Thrombosis and Haemostasis, 1999, 82, 974-982.	1.8	37
598	Revisiting Catalysis by Chymotrypsin Family Serine Proteases Using Peptide Substrates and Inhibitors with Unnatural Main Chains. Journal of Biological Chemistry, 1999, 274, 24074-24079.	1.6	39
599	Activation of Guanine Nucleotide-binding Proteins and Induction of Endothelial Tissue-type Plasminogen Activator Gene Transcription by Alcohol. Journal of Biological Chemistry, 1999, 274, 12055-12060.	1.6	15
600	Baboon Model of E. coli Sepsis: Role of Phospholipid Microparticles in DIC. Sepsis, 1999, 3, 125-134.	0.5	2
601	Relative Insufficiency of the Fibrinolytic System in Disseminated Intravascular Coagulation. Sepsis, 1999, 3, 119-124.	0.5	4
602	Effect of recombinant forms of urokinase plasminogen activator on platelet aggregation and intracellular calcium accumulation. Bulletin of Experimental Biology and Medicine, 1999, 128, 952-955.	0.3	0
603	Local recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy in microvascular surgery. , 1999, 19, 265-271.		29
604	Fibrinolysis and thrombosis. Best Practice and Research in Clinical Haematology, 1999, 12, 423-433.	0.7	82
605	Coagulation and fibrinolysis in cutaneous vasculitis. Clinics in Dermatology, 1999, 17, 615-618.	0.8	8

#	Article	IF	Citations
606	A Fibrinolytic Metalloprotease from the Fruiting Bodies of an Edible Mushroom,Armillariella mellea. Bioscience, Biotechnology and Biochemistry, 1999, 63, 2130-2136.	0.6	85
607	The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop 1 1Edited by A. R. Fersht. Journal of Molecular Biology, 1999, 293, 613-627.	2.0	25
608	Fatal varicella with primary fibrinolysis in a renal transplant recipient. Nephrology Dialysis Transplantation, 1999, 14, 1291-1294.	0.4	5
609	Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats. Neurological Research, 2000, 22, 413-419.	0.6	15
610	Fast quantitation of recombinant plasminogen activator inhibitor type 1 in bacterial lysates by micropellicular reversed-phase liquid chromatography. Journal of Chromatography A, 2000, 891, 85-92.	1.8	1
611	Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator. FEBS Journal, 2000, 267, 6378-6384.	0.2	14
612	Effective lysis of model thrombi by a tâ€PA mutant (A473S) that is resistant to Î±₂â€antiplasmin. British Journal of Haematology, 2000, 111, 517-523.	1.2	1
613	Recent advances in cardiovascular pharmacology. Current Problems in Cardiology, 2000, 25, 221-296.	1.1	3
614	On the mechanism of plasmin-induced platelet aggregation. Biochemical Pharmacology, 2000, 59, 1345-1355.	2.0	27
615	Molecular basis of thrombolytic therapy. Journal of Nuclear Cardiology, 2000, 7, 373-381.	1.4	7
616	The plasminogen activation system in tumor growth, invasion, and metastasis. Cellular and Molecular Life Sciences, 2000, 57, 25-40.	2.4	864
617	Induction of tissue plasminogen activator secretion from rat heart microvascular cells by fM 1,25(OH)₂D₃. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E293-E301.	1.8	12
619	Progressive and Transient Expression of Tissue Plasminogen Activator During Fetal Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1668-1674.	1.1	19
620	Cerebral venous thrombosis: anticoagulants or thrombolyic therapy?. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 427-430.	0.9	54
621	The renin-angiotensin-aldosterone system and fibrinolysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 240-244.	1.0	22
622	The Development of Bleomycin-Induced Pulmonary Fibrosis in Mice Deficient for Components of the Fibrinolytic System. American Journal of Pathology, 2000, 157, 177-187.	1.9	164
623	Effect of thrombomodulin on plasminogen activation. Fibrinolysis and Proteolysis, 2000, 14, 221-228.	1.1	10
624	Recent developments in thrombolytic therapy. Fibrinolysis and Proteolysis, 2000, 14, 66-72.	1.1	16

#	Article	IF	Citations
625	Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines. Clinica Chimica Acta, 2000, 296, 17-33.	0.5	17
626	An Inhibitor of Activated Thrombin-Activatable Fibrinolysis Inhibitor Potentiates Tissue-Type Plasminogen Activator-Induced Thrombolysis in a Rabbit Jugular Vein Thrombolysis Model. Thrombosis Research, 2000, 98, 333-342.	0.8	127
627	Increased D-dimer Levels in Twin Gestation. Thrombosis Research, 2000, 98, 485-489.	0.8	21
628	Thrombotic Dysfibrinogenemia. Thrombosis Research, 2000, 99, 187-193.	0.8	24
629	High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system. Journal of Vascular Surgery, 2000, 32, 374-382.	0.6	10
630	Thrombolytic Therapy in Acute Myocardial Infarction. Drugs and Aging, 2000, 16, 301-312.	1.3	4
631	Plasminogen-enriched Pulse-Spray Thrombolysis with tPA: Further Developments. Journal of Vascular and Interventional Radiology, 2000, 11, 1353-1362.	0.2	8
632	The Contribution of Residues 192 and 193 to the Specificity of Snake Venom Serine Proteinases. Journal of Biological Chemistry, 2000, 275, 1823-1828.	1.6	37
634	The cell envelope-bound metalloprotease (camelysin) from Bacillus cereus is a possible pathogenic factor. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2001, 1537, 132-146.	1.8	36
635	Enzyme-Linked Immunosorbent Assay for the Specific Detection of Angiostatin-Like Plasminogen Moieties in Biological Samples. Thrombosis Research, 2001, 102, 53-59.	0.8	6
636	Characterization of a Metalloenzyme from a Wild Mushroom, Tricholoma saponaceum. Bioscience, Biotechnology and Biochemistry, 2001, 65, 356-362.	0.6	82
637	Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin. Thrombosis and Haemostasis, 2001, 85, 5-11.	1.8	122
638	Gene targeting in hemostasis. plasminogen. Frontiers in Bioscience - Landmark, 2001, 6, d555.	3.0	6
639	Plasmin Induces Local Thrombolysis without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit. Thrombosis and Haemostasis, 2001, 86, 739-745.	1.8	87
640	Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coagulation and Fibrinolysis, 2001, 12, 627-637.	0.5	25
641	Influence of Sugar Chain on Fibrin Affinity of Recombinant t-PA.. Biological and Pharmaceutical Bulletin, 2001, 24, 295-298.	0.6	3
642	Effects of Aging on Luteinizing Hormone Secretion, Ovulation, and Ovarian Tissue-Type Plasminogen Activator Expression. Experimental Biology and Medicine, 2001, 226, 127-132.	1.1	12
643	Snake Venom Proteinases as Tools in Hemostasis Studies: Structure-Function Relationship of a Plasminogen Activator Purified from Trimeresurus stejnegeri Venom. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2001, 31, 133-140.	0.5	12

#	Article	IF	Citations
644	Pharmacokinetic studies of Gln117 tissue-type plasminogen activator in rats. Journal of Pharmaceutical and Biomedical Analysis, 2001, 26, 453-462.	1.4	5
645	Ectopic expression of the cAMP-responsive element binding protein inhibits phorbol ester-mediated induction of tissue-type plasminogen activator gene expression. FEBS Journal, 2001, 268, 987-996.	0.2	3
646	Lysine-derivatized polyurethane as a clot lysing surface: conversion of adsorbed plasminogen to plasmin and clot lysis in vitro. Biomaterials, 2001, 22, 1919-1924.	5.7	50
647	Activation of GÎ±s Mediates Induction of Tissue-type Plasminogen Activator Gene Transcription by Epoxyeicosatrienoic Acids. Journal of Biological Chemistry, 2001, 276, 15983-15989.	1.6	213
648	Localization of Regulatory Elements Mediating Constitutive and Cytokine-stimulated Plasminogen Gene Expression. Journal of Biological Chemistry, 2002, 277, 38579-38588.	1.6	19
649	Comparison of the inhibitory effects of two types (90â€‰kDa and 190â€‰kDa) of hyaluronic acid on the expression of fibrinolytic factors in human synovial fibroblasts. Modern Rheumatology, 2002, 12, 160-166.	0.9	5
650	Chimerism Reveals a Role for the Streptokinase Î²-Domain in Nonproteolytic Active Site Formation, Substrate, and Inhibitor Interactions. Journal of Biological Chemistry, 2002, 277, 26846-26851.	1.6	14
651	Plasminogen activator activity in cortical granules of bovine oocytes during in vitro maturation. Theriogenology, 2002, 57, 1897-1905.	0.9	17
652	Towards safer thrombolytic therapy. Seminars in Hematology, 2002, 39, 206-216.	1.8	37
654	The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. BBA - Proteins and Proteomics, 2002, 1596, 182-192.	2.1	59
655	Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. American Journal of Kidney Diseases, 2002, 39, 695-705.	2.1	49
656	Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis. European Journal of Pharmacology, 2003, 460, 1-8.	1.7	16
657	Fibrinogen gamma chain functions. Journal of Thrombosis and Haemostasis, 2003, 1, 231-238.	1.9	84
658	Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. Pathophysiology, 2003, 9, 103-109.	1.0	9
659	Hydrolysis of fibrinogen and plasminogen by immobilized earthworm fibrinolytic enzyme II from Eisenia fetida. International Journal of Biological Macromolecules, 2003, 32, 165-171.	3.6	28
660	Genetic polymorphisms of tâ€PA and PAIâ€1 genes in the Korean population. Korean Journal of Biological Sciences, 2003, 7, 249-253.	0.1	4
661	Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood, 2003, 101, 3002-3007.	0.6	66
662	Mechanisms of Thrombosis and thrombolysis. , 2004, , 785-798.		0

#	Article	IF	Citations
663	A Human t-PA Mutant cDNA Cassette Knocked in the Murine fgfr-4 Locus Targeting for Mammary Gland Expression. Acta Biochimica Et Biophysica Sinica, 2004, 36, 450-456.	0.9	0
664	Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice. Journal of Thrombosis and Haemostasis, 2004, 2, 1617-1621.	1.9	37
665	Tissue-type plasminogen activator: a historical perspective and personal account. Journal of Thrombosis and Haemostasis, 2004, 2, 541-546.	1.9	110
666	Salvage of free flaps after venous thrombosis: Case report. Microsurgery, 2004, 24, 298-301.	0.6	14
667	Foundation and sites of action of antithrombotic agents. Best Practice and Research in Clinical Haematology, 2004, 17, 3-22.	0.7	8
669	Thrombolytic agents. Thrombosis and Haemostasis, 2005, 93, 627-630.	1.8	144
670	Regulation of the single-chain urokinaseâ€“urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity. Blood, 2005, 105, 1021-1028.	0.6	8
671	Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen. Journal of Thrombosis and Haemostasis, 2005, 3, 146-153.	1.9	12
672	Pharmacokinetics and pharmacodynamics of BB-101531, a thrombin-activatable plasminogen, in healthy volunteers. Journal of Thrombosis and Haemostasis, 2005, 3, 1180-1186.	1.9	10
673	Fibrinogen and fibrin structure and functions. Journal of Thrombosis and Haemostasis, 2005, 3, 1894-1904.	1.9	1,382
674	Thrombolytic therapy in the management of acute limb ischaemia. British Journal of Surgery, 2005, 78, 261-269.	0.1	53
675	Fibrinolytic activity in the abdominal cavity of rats with faecal peritonitis. British Journal of Surgery, 2005, 81, 1046-1049.	0.1	64
676	Tissue plasminogen activator expression in meningiomas and glioblastomas. Clinical Neurology and Neurosurgery, 2005, 107, 296-300.	0.6	19
677	Normal Clotting. Seminars in Oncology Nursing, 2005, 21, 1-11.	0.7	5
678	Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Archives of Biochemistry and Biophysics, 2005, 433, 413-420.	1.4	168
679	Earthworm Fibrinolytic Enzyme. Studies in Natural Products Chemistry, 2005, 30, 825-847.	0.8	12
680	Biomarqueurs tissulaires tumoraux. Cancer du sein. Facteurs pronostiques, facteurs prÃ©dictifs. Quels standards en 2005 ?. , 2006, , 83-130.		0
681	The Structure and Biological Features of Fibrinogen and Fibrin. Annals of the New York Academy of Sciences, 2001, 936, 11-30.	1.8	504

#	Article	IF	Citations
682	Urokinase plasminogen activator and TGF-Î²2 production in immunosuppressed patients with and without P. Jiroveci infection. Microbial Pathogenesis, 2006, 41, 1-9.	1.3	3
683	Normal Cutaneous Wound Healing: Clinical Correlation with Cellular and Molecular Events. Dermatologic Surgery, 2005, 31, 674-686.	0.4	336
684	Plasminogen and plasmin activity in patients with coronary artery disease. Journal of Thrombosis and Haemostasis, 2006, 4, 1288-1295.	1.9	22
685	Elements of the Fibrinolytic System. Annals of the New York Academy of Sciences, 2001, 936, 226-236.	1.8	201
686	Fibrin Degradation Products. Annals of the New York Academy of Sciences, 2001, 936, 594-610.	1.8	47
687	Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. European Journal of Oral Sciences, 2006, 114, 22-26.	0.7	15
688	The Influence of Age on in vitro Plasmin Generation in the Presence of Fibrin Monomer. Acta Haematologica, 2006, 115, 141-151.	0.7	12
689	Intra-arterial Tissue Plasminogen Activator. Annals of Plastic Surgery, 2007, 59, 520-525.	0.5	21
690	Effects of KAATSU training on haemostasis in healthy subjects. International Journal of KAATSU Training Research, 2007, 3, 11-20.	0.3	30
691	Eisenia fetida Protease-III-1 Functions in Both Fibrinolysis and Fibrogenesis. Journal of Biomedicine and Biotechnology, 2007, 2007, 1-10.	3.0	16
692	Hormone Therapy and Hemostasis. , 2007, , 481-490.		1
693	Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining. International Journal of Cancer, 1991, 48, 20-27.	2.3	31
694	The Effect of Mouse Hepatitis Virus Infection on the Microcirculation of the Liver. Hepatology, 2007, 3, 964-973.	3.6	47
695	Mechanism of action of Î¸-amino acids on plasminogen activation and fibrinolysis induced by staphylokinase. Biochemistry (Moscow), 2007, 72, 707-715.	0.7	7
696	The C-terminus of ?2-antiplasmin interacts with endothelial cells. British Journal of Haematology, 2007, 136, 472-479.	1.2	15
697	Development of a new test for the global fibrinolytic capacity in whole blood. Journal of Thrombosis and Haemostasis, 2008, 6, 151-157.	1.9	32
698	A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. Journal of Thrombosis and Haemostasis, 2008, 6, 944-950.	1.9	30
699	Purification and properties of plasminogen activators from epithelial cells. FEBS Journal, 2008, 147, 511-516.	0.2	17

#	Article	IF	Citations
700	The Speciesâ€Specific Differences in the cAMP Regulation of the Tissueâ€Type Plasminogen Activator Gene between Rat, Mouse and Human is Caused by a Oneâ€Nucleotide Substitution in the cAMPâ€Responsive Element of the Promoters. FEBS Journal, 1995, 231, 466-474.	0.2	10
701	Purification and characterization of fibrinolytic metalloprotease from Perenniporia fraxinea mycelia. Mycological Research, 2008, 112, 990-998.	2.5	45
702	Plasminogen activator induction facilitates recovery of respiratory function following spinal cord injury. Molecular and Cellular Neurosciences, 2008, 37, 143-152.	1.0	17
703	Bleeding That Wonâ€™t Stop. Annals of Thoracic Surgery, 2008, 85, 1153-1154.	0.7	9
704	Pre-clinical studies of plasmin: Superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator. Thrombosis Research, 2008, 122, S9-S15.	0.8	22
705	Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion. Thrombosis Research, 2008, 122, S16-S19.	0.8	6
706	The Kringle Domain of Tissue-Type Plasminogen Activator Inhibits Extracellular Matrix-Induced Adhesion and Migration of Endothelial Cells. Bioscience, Biotechnology and Biochemistry, 2008, 72, 2303-2308.	0.6	2
707	Effect of plasmin, plasminogen activators and a plasmin inhibitor on bovine in vitro embryo production. Reproduction, Fertility and Development, 2008, 20, 320.	0.1	21
708	Role of plasminogen activator in spinal cord remodeling after spinal cord injury. Respiratory Physiology and Neurobiology, 2009, 169, 141-149.	0.7	13
709	The Role of the Fibrinolytic System in Thrombotic Disease. Acta Medica Scandinavica, 1987, 221, 169-171.	0.0	6
710	A Family with Reduced Plasminogen Activator Activity in Blood Associated with Recurrent Venous Thrombosis. Scandinavian Journal of Haematology, 1982, 29, 217-223.	0.0	51
711	Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials, 2009, 30, 5125-5130.	5.7	107
712	New insights into the molecular mechanisms of the fibrinolytic system. Journal of Thrombosis and Haemostasis, 2009, 7, 4-13.	1.9	315
714	The Tissue-Type Plasminogen Activator Story. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1151-1155.	1.1	95
715	Disseminated intravascular coagulation in cancer patients. Best Practice and Research in Clinical Haematology, 2009, 22, 129-136.	0.7	80
716	Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. Thrombosis Research, 2009, 123, S56-S61.	0.8	31
717	Thrombolysis With Plasmin. Stroke, 2010, 41, S45-9.	1.0	47
718	Role of Tissue-Type Plasminogen Activator in Ischemic Stroke. Journal of Pharmacological Sciences, 2010, 113, 203-207.	1.1	27

#	Article	IF	Citations
721	Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. Journal of Thrombosis and Haemostasis, 2010, 8, 433-444.	1.9	66
722	The molecular basis of thrombolysis and its clinical application in stroke. Journal of Internal Medicine, 2010, 267, 191-208.	2.7	90
723	Thrombolysis in children. British Journal of Haematology, 2010, 148, 26-36.	1.2	37
724	Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization. Nature, 2010, 465, 478-482.	13.7	152
725	Reperfusion Therapies for Acute ST Segment Elevation Myocardial Infarction. , 2010, , 110-144.		0
726	Earthworm Protease. Applied and Environmental Soil Science, 2010, 2010, 1-13.	0.8	26
727	Epoxyeicosatrienoic Acid Analogs and Vascular Function. Current Medicinal Chemistry, 2010, 17, 1181-1190.	1.2	103
728	Managing Fibrinolysis Without Aprotinin. Annals of Thoracic Surgery, 2010, 89, 324-331.	0.7	30
729	Function and Expression of the uPA/uPAR System in Cancer Metastasis. , 0, , 223-236.		1
730	Plasminogen Activator Promotes Recovery Following Spinal Cord Injury. Cellular and Molecular Neurobiology, 2011, 31, 961-967.	1.7	16
731	Intravenous Thrombolytics for Ischemic Stroke. Neurotherapeutics, 2011, 8, 388-399.	2.1	49
732	Pathogenesis of postoperative adhesion formation. British Journal of Surgery, 2011, 98, 1503-1516.	0.1	191
734	Herpesviruses enhance fibrin clot lysis. Thrombosis and Haemostasis, 2012, 107, 760-768.	1.8	7
735	Expression and large-scale production of the biochemically active human tissue-plasminogen activator in hairy roots of Oriental melon (Cucumis melo). Journal of Bioscience and Bioengineering, 2012, 113, 106-111.	1.1	28
736	Serine-proteases as plasminogen activators in terms of fibrinolysis. Journal of Pharmacy and Pharmacology, 2012, 64, 1025-1039.	1.2	35
737	t-Plasminogen Activator. , 2013, , 2946-2952.		0
738	Current Practices in Preclinical Drug Development. Toxicologic Pathology, 2013, 41, 445-453.	0.9	27
740	Blood Component and Pharmacologic Therapy for Hemostatic Disorders. , 2013, , 496-525.		3

#	Article	IF	Citations
741	Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery. British Journal of Anaesthesia, 2013, 110, 788-799.	1.5	27
742	Normal Coagulation and Hemostasis. , 2014, , 1544-1552.		2
743	Blood-aggregating hydrogel particles for use as a hemostatic agent. Acta Biomaterialia, 2014, 10, 701-708.	4.1	130
744	The role of astrocytes in mediating exogenous cellâ€based restorative therapy for stroke. Glia, 2014, 62, 1-16.	2.5	74
745	Purification and characterization of a novel fibrinolytic Î± chymotrypsin like serine metalloprotease from the edible mushroom, Lyophyllum shimeji. Journal of Bioscience and Bioengineering, 2014, 117, 544-550.	1.1	33
746	Co-expression of disulfide oxidoreductases DsbA/DsbC markedly enhanced soluble and functional expression of reteplase in Escherichia coli. Journal of Biotechnology, 2014, 192, 197-203.	1.9	10
747	Cancer-related coagulopathies. Thrombosis Research, 2014, 133, S70-S75.	0.8	44
748	Serum level of Urokinase Plasminogen Activator (uPA) Correlates with the Survival of Patients with Pancreatic Ductal Adenocarcinoma (PDAC). Pancreatic Disorders & Therapy, 2015, 05, .	0.3	2
750	Efficacy and mechanism of tanshinone IIA liquid nanoparticles in preventing experimental postoperative peritoneal adhesions in vivo and in vitro. International Journal of Nanomedicine, 2015, 10, 3699.	3.3	9
751	Pharmacological modulation of fibrinolytic response â€“ In vivo and in vitro studies. Pharmacological Reports, 2015, 67, 695-703.	1.5	13
753	Prospective Evaluation of Blood Coagulability and Effect of Treatment in Patients with Stroke Using Rotational Thromboelastometry. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 304-311.	0.7	9
754	Recombinant tissue plasminogen activators (rtPA): A review. Clinical Pharmacology and Therapeutics, 2015, 97, 274-285.	2.3	42
755	Predisposing factors to post-operative adhesion development. Human Reproduction Update, 2015, 21, 536-551.	5.2	73
756	Penta-<scp>l</scp>-lysine Potentiates Fibrin-Independent Activity of Human Tissue Plasminogen Activator. Journal of Physical Chemistry B, 2015, 119, 13271-13277.	1.2	4
757	Effects of Addition of Tissueâ€Type Plasminogen Activator in In Vitro Fertilization Medium on Bovine Embryo Development and Quality. Reproduction in Domestic Animals, 2015, 50, 112-120.	0.6	11
758	Purification and characterization of a fibrinolytic enzyme from Petasites japonicus. International Journal of Biological Macromolecules, 2015, 72, 1159-1167.	3.6	30
759	Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation. Frontiers in Cellular Neuroscience, 2016, 10, 154.	1.8	4
760	Plasmin-Antiplasmin System. , 2016, , 31-51.		2

#	Article	IF	Citations
761	Management of cancer-associated disseminated intravascular coagulation. Thrombosis Research, 2016, 140, S66-S70.	0.8	42
762	A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo. Blood, 2016, 127, 1085-1096.	0.6	33
763	Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke. Expert Opinion on Biological Therapy, 2016, 16, 1323-1340.	1.4	15
764	The story of an exceptional serine protease, tissue-type plasminogen activator (tPA). Revue Neurologique, 2016, 172, 186-197.	0.6	37
765	Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 629-635.	1.1	4
766	Translational initiatives in thrombolytic therapy. Frontiers of Medicine, 2017, 11, 1-19.	1.5	17
767	Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Singleâ€€Chain Antibody Specific for Activated GPIIb/IIIa. Journal of the American Heart Association, 2017, 6, .	1.6	22
768	Development and validation of a high throughput whole blood thrombolysis plate assay. Scientific Reports, 2017, 7, 2346.	1.6	27
769	Effect of urokinase type plasminogen activator on in vitro bovine oocyte maturation. Reproduction, 2017, 154, 331-340.	1.1	6
770	Plasminogenâ€“receptor KT: plasminogen activation and beyond. Journal of Thrombosis and Haemostasis, 2017, 15, 150-154.	1.9	9
771	Bletilla striataMicron Particles Function as a Hemostatic Agent by Promoting Rapid Blood Aggregation. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-8.	0.5	5
772	Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts. PLoS ONE, 2017, 12, e0180668.	1.1	18
773	An in vitro proof-of-principle study of sonobactericide. Scientific Reports, 2018, 8, 3411.	1.6	16
774	Diversity and functional evolution of the plasminogen activator system. Biomedicine and Pharmacotherapy, 2018, 98, 886-898.	2.5	43
775	Properties of Bioconjugates of Streptokinase with Anionic Polyamidoamine Dendrimers of Various Generations. Russian Journal of Bioorganic Chemistry, 2018, 44, 528-537.	0.3	1
776	Coagulation and anticoagulation in the intraoperative setting. Transfusion and Apheresis Science, 2019, 58, 386-391.	0.5	5
777	Phase 2, randomized, open-label study on catheter-directed thrombolysis with plasmin versus rtPA and placebo in acute peripheral arterial occlusion. Journal of Drug Assessment, 2019, 8, 43-54.	1.1	2
778	Disseminated Intravascular Coagulation in Cancer: An Update. Seminars in Thrombosis and Hemostasis, 2019, 45, 342-347.	1.5	50

#	Article	IF	Citations
779	Pro-resolving lipid mediators as therapeutic leads for cardiovascular diseases. Expert Opinion on Therapeutic Targets, 2019, 23, 423-436.	1.5	13
780	The time course of acute Percheron artery ischemic coma on imaging: A retrospective cohort study. Brain Research Bulletin, 2020, 165, 298-304.	1.4	0
781	Evaluation of the Effects of Peritoneal Lavage with Rosmarinus officinalis Extract against the Prevention of Postsurgical-Induced Peritoneal Adhesion. Planta Medica, 2020, 86, 405-414.	0.7	24
782	The Plasmin System in Milk and Dairy Products. Food Engineering Series, 2021, , 11-55.	0.3	3
783	The fibrinolytic system in the cornea: A key regulator of corneal wound healing and biological defense. Experimental Eye Research, 2021, 204, 108459.	1.2	10
784	Disseminated Intravascular Coagulation. Seminars in Oncology Nursing, 2021, 37, 151135.	0.7	6
785	Investigating the Multifaceted Nature of Radiation-Induced Coagulopathies in a GÃ¶ttingen Minipig Model of Hematopoietic Acute Radiation Syndrome. Radiation Research, 2021, 196, 156-174.	0.7	0
786	Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology, 2021, 12, 627533.	1.6	24
787	Physiological Functions of Plasminogen Activation: Effects of Gene Deficiencies in Humans and Mice. , 2008, , 183-201.		2
788	Blood Compatibility in Cardiopulmonary Bypass. , 1992, , 37-79.		6
789	The Fibrinolytic System of Cultured Endothelial Cells. , 1988, , 229-252.		2
790	Effects of Structural Modifications on the Properties of Tissue Plasminogen Activator (tPA). Advances in Experimental Medicine and Biology, 1990, 281, 185-194.	0.8	2
791	New Developments in Thrombolytic Therapy. Advances in Experimental Medicine and Biology, 1990, , 333-354.	0.8	12
792	Monoclonal Antibodies for the Detection of Thrombosis. Advances in Experimental Medicine and Biology, 1990, 281, 419-427.	0.8	4
793	Structure of the Genes Encoding Proteins Involved in Blood Clotting. , 1988, , 265-330.		1
794	Signal Transduction Chains Involved in the Control of the Fibrinolytic Enzyme Cascade. , 1990, , 127-135.		3
795	A Key Molecule Dictating and Regulating Surface Plasmin Formation : The Receptor for Urokinase Plasminogen Activator. , 1990, , 21-30.		2
796	Structure and Function of Tissue-Type Plasminogen Activator. , 1990, , 51-68.		4

#	Article	IF	Citations
797	Molecular Mechanism of Fibrinolysis. Advances in Experimental Medicine and Biology, 1984, 164, 217-228.	0.8	3
798	Endothelial Cell Function in Hemostasis and Thrombosis. Advances in Experimental Medicine and Biology, 1988, 242, 127-133.	0.8	24
799	Proteolytic Mechanisms Operating at the Surface of Invasive Cells. Advances in Experimental Medicine and Biology, 1988, 233, 187-199.	0.8	14
800	PAI-1, Obesity, and Insulin Resistance. , 1999, , 317-332.		5
801	Pharmacokinetics and Pharmacodynamics of Fibrinolytic Agents. , 2015, , 19-39.		1
802	Plasminogen and Streptokinase. Handbook of Experimental Pharmacology, 2001, , 25-56.	0.9	2
803	Hemostasis and Coagulation. , 2001, , 161-176.		4
804	Hemostasis in Xenotransplantation. , 1997, , 126-139.		1
805	Thrombosis and Cerebrovascular Disease. , 1987, , 59-74.		14
806	Fibrinolysis and Fibrinolytic Drugs. Handbook of Experimental Pharmacology, 1989, , 279-300.	0.9	1
807	Relationships Among the Complement, Kinin, Coagulation, and Fibrinolytic Systems. , 1985, , 379-406.		3
809	Fibrin Polymerization and its Role in Regulating Hemostasis. , 1990, , 27-43.		3
810	Regulation of Fibrinolysis: Plasminogen Activator as a Thrombolytic Agent. , 1982, , 183-189.		9
811	Pharmacological and Biochemical Actions of the Salicylates. , 1984, , 67-147.		2
812	Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture. Journal of Biological Chemistry, 1990, 265, 20443-20448.	1.6	47
813	A novel regulatory sequence affecting the constitutive expression of tissue plasminogen activator (tPA) gene in human melanoma (Bowes) cells. Journal of Biological Chemistry, 1994, 269, 18558-18562.	1.6	10
814	Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.. Journal of Biological Chemistry, 1994, 269, 15989-15992.	1.6	20
815	Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.. Journal of Biological Chemistry, 1986, 261, 1267-1273.	1.6	108

#	Article	IF	Citations
816	Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa.. Journal of Biological Chemistry, 1985, 260, 13666-13676.	1.6	180
817	Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants.. Journal of Biological Chemistry, 1985, 260, 11581-11587.	1.6	503
818	Isolation and characterization of a urokinase-type plasminogen activator (Mr = 54,000) from cultured human endothelial cells indistinguishable from urinary urokinase.. Journal of Biological Chemistry, 1984, 259, 7198-7205.	1.6	72
819	Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.. Journal of Biological Chemistry, 1984, 259, 14914-14921.	1.6	423
820	Plasminogen activation in diabetes mellitus. Kinetic analysis of plasmin formation using components isolated from the plasma of diabetic donors.. Journal of Biological Chemistry, 1984, 259, 2976-2981.	1.6	29
821	Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.. Journal of Biological Chemistry, 1984, 259, 2080-2083.	1.6	141
822	Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.. Journal of Biological Chemistry, 1993, 268, 18496-18501.	1.6	7
823	Human plasminogen. Proton NMR studies on kringle 1.. Journal of Biological Chemistry, 1982, 257, 12716-12721.	1.6	43
824	The effect of fibrin structure on fibrinolysis.. Journal of Biological Chemistry, 1992, 267, 24259-24263.	1.6	230
825	Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.. Journal of Biological Chemistry, 1988, 263, 15845-15848.	1.6	90
826	One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.. Journal of Biological Chemistry, 1988, 263, 11189-11195.	1.6	205
827	Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1.. Journal of Biological Chemistry, 1992, 267, 12412-12415.	1.6	93
828	Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.. Journal of Biological Chemistry, 1994, 269, 25529-25533.	1.6	6
829	Cellular catabolism of recombinant tissue-type plasminogen activator. Identification and characterization of a novel high affinity uptake system on rat hepatocytes.. Journal of Biological Chemistry, 1987, 262, 8716-8720.	1.6	52
830	Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals.. Journal of Biological Chemistry, 1992, 267, 597-601.	1.6	37
831	Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.. Journal of Biological Chemistry, 1991, 266, 2824-2830.	1.6	141
832	Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn2+ mediates strong and specific interaction of single-chain urokinase with fibrin.. Journal of Biological Chemistry, 1993, 268, 8574-8579.	1.6	16
833	The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator.. Journal of Biological Chemistry, 1993, 268, 5550-5556.	1.6	3

#	Article	IF	Citations
834	Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells.. Journal of Biological Chemistry, 1991, 266, 17845-17849.	1.6	59
835	Mutant and chimeric recombinant plasminogen activators. Production in eukaryotic cells and preliminary characterization.. Journal of Biological Chemistry, 1987, 262, 11771-11778.	1.6	35
836	cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta.. Journal of Biological Chemistry, 1987, 262, 3718-3725.	1.6	216
837	Identification of the Domains of Tissue-type Plasminogen Activator Involved in the Augmented Binding to Fibrin after Limited Digestion with Plasmin. Journal of Biological Chemistry, 1989, 264, 12604-12610.	1.6	60
838	On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid.. Journal of Biological Chemistry, 1986, 261, 14214-14218.	1.6	225
839	Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.. Journal of Biological Chemistry, 1986, 261, 11207-11213.	1.6	209
840	Isolation and interrelationships of the multiple molecular tissue-type and urokinase-type plasminogen activator forms produced by cultured human umbilical vein endothelial cells.. Journal of Biological Chemistry, 1988, 263, 15129-15138.	1.6	31
841	Purification and properties of a single-chain urokinase-type plasminogen activator form produced by subcultured human umbilical vein endothelial cells.. Journal of Biological Chemistry, 1988, 263, 15139-15145.	1.6	25
842	Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties.. Journal of Biological Chemistry, 1988, 263, 3971-3978.	1.6	71
843	Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes.. Journal of Biological Chemistry, 1988, 263, 2917-2924.	1.6	39
844	A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP.. Journal of Biological Chemistry, 1990, 265, 14618-14626.	1.6	129
845	Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.. Journal of Biological Chemistry, 1990, 265, 13547-13552.	1.6	34
846	Induction of fibrinolytic activity in HeLa cells by phorbol myristate acetate. Tissue-type plasminogen activator antigen and mRNA augmentation require intermediate protein biosynthesis.. Journal of Biological Chemistry, 1985, 260, 6354-6360.	1.6	71
847	Plasminogen Activation Initiated by Single-chain Urokinase-type Plasminogen Activator. Journal of Biological Chemistry, 1989, 264, 2185-2188.	1.6	305
848	On the mechanism of fibrin-specific plasminogen activation by staphylokinase. Journal of Biological Chemistry, 1991, 266, 11826-11832.	1.6	143
849	The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.. Journal of Biological Chemistry, 1994, 269, 12639-12644.	1.6	50
850	Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain.. Journal of Biological Chemistry, 1990, 265, 5170-5177.	1.6	27
851	Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).. Journal of Biological Chemistry, 1988, 263, 15454-15461.	1.6	431

#	Article	IF	Citations
852	Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.. Journal of Biological Chemistry, 1988, 263, 15688-15693.	1.6	41
853	The structure of the TATA-less rat tissue-type plasminogen activator gene. Species-specific sequence divergences in the promoter predict differences in regulation of gene expression.. Journal of Biological Chemistry, 1990, 265, 2022-2027.	1.6	61
854	Sequence and characterization of Bacillus subtilis CheW.. Journal of Biological Chemistry, 1992, 267, 12055-12060.	1.6	37
855	Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor.. Journal of Biological Chemistry, 1992, 267, 9668-9677.	1.6	40
856	Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.. Journal of Biological Chemistry, 1986, 261, 7644-7651.	1.6	208
857	Isolation of a prokaryotic plasmin receptor. Relationship to a plasminogen activator produced by the same micro-organism.. Journal of Biological Chemistry, 1991, 266, 4922-4928.	1.6	57
858	Component C of the methylreductase system of Methanobacterium.. Journal of Biological Chemistry, 1981, 256, 4259-4262.	1.6	156
859	Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region.. Journal of Biological Chemistry, 1987, 262, 13662-13673.	1.6	127
860	Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.. Journal of Biological Chemistry, 1982, 257, 2912-2919.	1.6	1,162
861	Isolation and characterization of urokinase from human plasma.. Journal of Biological Chemistry, 1982, 257, 3276-3283.	1.6	244
862	Vascular origin determines plasminogen activator expression in human endothelial cells. Journal of Biological Chemistry, 1989, 264, 2846-2852.	1.6	82
863	Structural domains of human tissue-type plasminogen activator that confer stimulation by heparin. Journal of Biological Chemistry, 1989, 264, 15441-15444.	1.6	42
864	Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. Journal of Lipid Research, 1997, 38, 860-869.	2.0	25
865	Laboratory Evaluation of Hypercoagulability. Clinics in Haematology, 1981, 10, 407-442.	2.2	23
866	Acquired Coagulation Disorders. Clinics in Haematology, 1985, 14, 413-442.	2.2	58
867	The Fibrinolytic System of the Vascular Wall. Clinics in Haematology, 1985, 14, 513-530.	2.2	125
868	The Role of Endothelium in the Homeostatic Balance of Haemostasis. Clinics in Haematology, 1985, 14, 531-546.	2.2	41
869	Thrombolysis in Acute Myocardial infarction. Cardiology Clinics, 1988, 6, 119-137.	0.9	8

#	Article	IF	Citations
870	Coronary Thrombolysis with TissueType Plasminogen Activator. Cardiology Clinics, 1987, 5, 101-111.	0.9	3
871	Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin. British Journal of Haematology, 2000, 111, 517-523.	1.2	8
872	Mechanisms of Signaling through Urokinase Receptor and the Cellular Response. Thrombosis and Haemostasis, 1999, 82, 305-311.	1.8	42
873	Influence of Intrinsic and Extrinsic Plasminogen upon the Lysis of Thrombi In Vitro. Thrombosis and Haemostasis, 1991, 66, 672-677.	1.8	23
874	An Enzyme-Linked Immunosorbent Assay (ELISA) Used to Study the Cellular Secretion of Endothelial Plasminogen Activator Inhibitor (PAI-1). Thrombosis and Haemostasis, 1988, 59, 068-072.	1.8	29
875	Role of Urokinase Type Plasminogen Activator (u-PA) in Corneal Epithelial Migration. Thrombosis and Haemostasis, 1993, 69, 387-391.	1.8	52
877	Plasminogen Activation by Invasive Human Pathogens. Thrombosis and Haemostasis, 1997, 77, 001-010.	1.8	166
878	Ultrasensitive Fluorogenic Substrates for Serine Proteases. Thrombosis and Haemostasis, 1997, 78, 1193-1201.	1.8	29
879	Immunodetection of Human Fibrin Using Monoclonal Antibody-64C5 in an Extracorporeal Chicken Model. Thrombosis and Haemostasis, 1985, 54, 524-527.	1.8	19
880	Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA. Thrombosis and Haemostasis, 1985, 54, 684-687.	1.8	204
881	Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase â€“ I. Fibrinolytic and Fibrinogenolytic Properties in Human Plasma In Vitro of Urokinases Obtained from Human Urine or by Recombinant DNA Technology. Thrombosis and Haemostasis, 1984, 52, 019-023.	1.8	135
882	Distinct Contributions of Residue 192 to the Specificity of Coagulation and Fibrinolytic Serine Proteases. Journal of Biological Chemistry, 1999, 274, 7153-7156.	1.6	5
883	The Species-Specific Differences in the cAMP Regulation of the Tissue-Type Plasminogen Activator Gene between Rat, Mouse and Human is Caused by a One-Nucleotide Substitution in the cAMP-Responsive Element of the Promoters. FEBS Journal, 1995, 231, 466-474.	0.2	23
884	Identification of a specific receptor for plasmin on a group A streptococcus. Infection and Immunity, 1987, 55, 1914-1918.	1.0	124
885	Mapping of the human plasmin domain recognized by the unique plasmin receptor of group A streptococci. Infection and Immunity, 1989, 57, 2597-2605.	1.0	36
886	Acquisition of Plasmin Activity by Fusobacterium nucleatum subsp. nucleatum and Potential Contribution to Tissue Destruction during Periodontitis. Infection and Immunity, 1999, 67, 6439-6444.	1.0	44
887	Species Specificity of Plasminogen Activation and Acquisition of Surface-Associated Proteolytic Activity by Group C Streptococci Grown in Plasma. Infection and Immunity, 1999, 67, 6487-6495.	1.0	27
888	Superficial Accumulation of Plasminogen During Plasma Clot Lysis. Circulation, 1995, 92, 1883-1890.	1.6	108

#	Article	IF	Citations
889	Management of Deep Vein Thrombosis and Pulmonary Embolism. Circulation, 1996, 93, 2212-2245.	1.6	553
890	Fibrin-Selective Thrombolytic Therapy for Acute Myocardial Infarction. Circulation, 1996, 93, 857-865.	1.6	76
891	Brain Capillary Tissue Plasminogen Activator in a Diabetes Stroke Model. Stroke, 1996, 27, 712-719.	1.0	41
892	Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon aminocaproic acid.. Journal of Clinical Investigation, 1983, 71, 159-164.	3.9	11
893	Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.. Journal of Clinical Investigation, 1984, 74, 571-580.	3.9	63
894	Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.. Journal of Clinical Investigation, 1984, 74, 1465-1472.	3.9	338
895	A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.. Journal of Clinical Investigation, 1985, 75, 413-419.	3.9	75
896	Plasmin inhibition of platelet function and of arachidonic acid metabolism.. Journal of Clinical Investigation, 1985, 75, 456-461.	3.9	141
897	Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.. Journal of Clinical Investigation, 1986, 78, 138-144.	3.9	21
898	Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin.. Journal of Clinical Investigation, 1986, 78, 73-79.	3.9	118
899	Effects of sulfonylureas on the synthesis and secretion of plasminogen activator from bovine aortic endothelial cells.. Journal of Clinical Investigation, 1988, 81, 730-737.	3.9	19
900	Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.. Journal of Clinical Investigation, 1988, 81, 853-859.	3.9	129
901	Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase.. Journal of Clinical Investigation, 1988, 82, 1877-1883.	3.9	67
902	Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.. Journal of Clinical Investigation, 1989, 84, 647-655.	3.9	91
903	Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.. Journal of Clinical Investigation, 1991, 88, 1155-1160.	3.9	99
904	The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.. Journal of Clinical Investigation, 1993, 92, 978-983.	3.9	26
905	alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.. Journal of Clinical Investigation, 1994, 93, 703-710.	3.9	53
906	Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood, 1984, 64, 907-913.	0.6	122

#	Article	IF	Citations
907	Disease Severity Is Correlated with Plasma Clotting and Fibrinolytic and Kinin-Kallikrein Activity in Neonatal Respiratory Distress Syndrome. Pediatric Research, 1997, 41, 120-127.	1.1	27
908	Increased Tissue-Type Plasminogen Activator Antigen Release Is Not Accompanied by Increased Systemic Fibrinolytic Activity in Severe Neonatal Respiratory Distress Syndrome. Pediatric Research, 1999, 45, 588-594.	1.1	10
909	Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests. Pediatric Research, 2003, 53, 333-337.	1.1	19
910	The expression of endothelial tissue plasminogen activator in vivo: a function defined by vessel size and anatomic location. Journal of Cell Science, 1997, 110, 139-148.	1.2	99
911	Thrombolytic properties of an inactive proenzyme form of human urokinase secreted from human kidney cells.. Cell Structure and Function, 1985, 10, 151-159.	0.5	19
912	Co-localization of Urokinase and its Receptor on Established Human Umbilical Vein Endothelial Cell.. Cell Structure and Function, 1999, 24, 71-78.	0.5	5
913	Functional Implication of Secretory Proteases Derived from Microglia in the Central Nervous System.. Keio Journal of Medicine, 1996, 45, 263-269.	0.5	5
914	Activation of Blood Coagulation and Fibrinolysis in Selected Disease States Assessed by Plasma Levels of Thrombin-Antithrombin III Complex and Plasmin-Î±2-Plasmin Inhibitor Complex. Japanese Journal of Thrombosis and Hemostasis, 1990, 1, 502-511.	0.1	6
915	Behaviours of tissue plasminogen activator(t-PA) in various hematologic disease, liver disease, diabetes mellitus, collagen disease, thrombotic disease, and disseminated intravascular coagulation(DIC): Quantitative measurement of plasma t-PA by a one-step ELISA.. Blood & Vessel, 1989, 20, 240-249.	0.0	1
916	Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2020, 11, 93-109.	0.6	11
917	Fifty Years of Acute Ischemic Stroke Treatment: A Personal History. Cerebrovascular Diseases, 2021, 50, 666-680.	0.8	13
918	Drugs in Development: New Agents, New Classes, New Indications. , 2000, , 273-291.		0
919	Desmodus rotundus (Common Vampire Bat) Salivary Plasminogen Activator. Handbook of Experimental Pharmacology, 2001, , 451-472.	0.9	3
920	Thrombolytika. , 2002, , 158-177.		0
921	Basic Aspects of Fibrinolysis and Thrombolysis. , 2002, , 62-71.		0
922	Clinical and Research Applications of Markers of Thrombosis. , 2006, , 451-466.		0
924	Interactions entre les cellules tumorales et le microenvironnement tissulaire : Â« Quand le dialogue remplace le monologue Â». , 2007, , 97-123.		0
926	Hemostasis and Coagulation. , 2008, , 149-165.		2

#	Article	IF	Citations
927	Overview of Established and New Thrombolytics. Fundamental and Clinical Cardiology, 2009, , 563-578.	0.0	0
929	Coma from â€œTop of the Basilar Arteryâ€•Ischemic Stroke: Is Irreversible Coma?. Advances in Clinical Medicine, 2011, 01, 17-20.	0.0	0
930	Mechanisms of Thrombosis and Thrombolysis. , 2011, , 29-43.		0
931	Progress of Thrombolytic Therapy and its Clinical Effect. Blood & Vessel, 1981, 12, 493-501.	0.0	0
932	Symposium Fibrinogen. Verhandlungen Der Deutschen Gesellschaft Fur Innere Medizin, 1982, , 1261-1292.	0.0	0
933	On the fibrinolytic properties of human tissue plasminogen activator. Blood & Vessel, 1982, 13, 344-346.	0.0	0
934	Overview on Blood Coagulation Proteins. , 1984, , 39-55.		0
935	Elimination des Fibrins. , 1984, , 25-37.		1
936	Impairment of Fibrinolysis as a Risk Factor for Thrombosis. , 1984, , 411-415.		0
937	StÃ¶rungen der HÃmostase. , 1984, , 453-487.		0
938	Impairment of Fibrinolysis and Vascular Disease. Advances in Experimental Medicine and Biology, 1984, 164, 49-56.	0.8	0
939	Studies on Kallikrein-Kinin system in liver diseases. Blood & Vessel, 1984, 15, 128-134.	0.0	1
940	Biological and Thrombolytic Properties of Natural and Recombinant Human Tissue-Type Plasminogen Activator (t-PA). , 1985, , 17-23.		0
941	Novel Thrombolytic Drugs. , 1985, , 55-62.		0
943	Mapping Tissue Plasminogen Activator and Urokinase Genes to Human Chromosomes. Protides of the Biological Fluids; Proceedings of the Colloquium, 1985, , 99-101.	0.1	1
944	The Biochemistry of Thrombolytic Agents. , 1985, , 61-66.		0
945	Fragment K 2-3 of plasminogen molecule carries a lysine-binding site. Biopolymers and Cell, 1986, 2, 19-23.	0.1	0
946	Fibrin-Specific Thrombolysis with Tissue-Type Plasminogen Activator and Single Chain Urokinase-Type Plasminogen Activator. Update in Intensive Care and Emergency Medicine, 1986, , 167-168.	0.6	0

#	Article	IF	Citations
947	Pro-urokinase and tissue-type plasminogen activator. , 1986, , 13-18.		0
948	The Fibrinolytic System of Cultured Endothelial Cells. , 1987, , 283-289.		1
949	The Fibrinolytic System of Cultured Bovine Aortic Endothelial Cells. , 1987, , 140-144.		0
950	Fibrinolytische Parameter bei Patienten einer Koronarsportgruppe. , 1987, , 805-808.		0
951	Die EuropÃischen rt-PA-Studien beim akuten Myokardinfarkt. , 1987, , 75-99.		2
952	Prevention of Clot Formation in Cat Retinal Vein by Systemic and Subconjunctival Urokinase. Documenta Ophthalmologica Proceedings Series, 1987, , 65-75.	0.0	0
953	Evaluation of hyperfibrinolysis by measuring plasmin-.ALPHA.2 plasmin inhibitor complex in plasma: Studies in disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, primary fibrinolysis and during fibrinolytic therapy.. Blood & Vessel, 1988, 19, 82-92.	0.0	0
954	The Arterial Wall and the Haemostatic Process. , 1989, , 127-141.		0
955	Fibrinolytic Response to Standardized Venous Occlusion in Different Age Groups. Korean Journal of Internal Medicine, 1989, 4, 48-54.	0.7	3
956	Fibrinolysis. , 1989, , 179-215.		0
957	Biological Properties of Hybrid Plasminogen Activators. Advances in Experimental Medicine and Biology, 1990, 281, 201-208.	0.8	0
958	Analysis of Fibrinolytic States by Differential Quantification of Fibrinogen Degradation Products and Fibrin Degradation Products. Japanese Journal of Thrombosis and Hemostasis, 1990, 1, 123-133.	0.1	0
959	Fibrin-specific Clot Lysis with Single Chain Urokinase-type Plasminogen Activator (scu-PA). , 1990, , 232-240.		0
960	Fibrinolytic Treatment with Tissue-Type Plasminogen Activator (t-PA) of Streptococcus Sanguis Endocarditis. , 1990, , 429-434.		0
961	Possible involvement of endothelium-granulocyte interaction in acute gastric mucosal lesions. Participation of platelet-activating factor.. Ensho, 1990, 10, 119-124.	0.0	0
962	Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.. Journal of Biological Chemistry, 1990, 265, 10473-10478.	1.6	12
963	Neuere Aspekte des Gerinnungs und Fibrinolysesystems. , 1991, , 129-136.		0
964	Fibrinolysis: Thrombolytic Agents, Mechanisms, and New Developments. , 1991, , 9-23.		0

#	Article	IF	Citations
965	Fibrinogen and Fibrin Formation and Its Role in Fibrinolysis. , 1991, 19, 225-279.		4
967	Mechanisms of Haemostasis. , 1992, , 117-127.		0
968	Studies and perspectives of plasminogen activators. Biomedical Reviews, 2014, 1, 33.	0.6	1
969	Transcriptional regulation of the rat tissue type plasminogen activator gene: localization of DNA elements and nuclear factors mediating constitutive and cyclic AMP-induced expression. Molecular and Cellular Biology, 1993, 13, 266-275.	1.1	12
970	Selected Disorders of the Blood and Hematopoietic System. , 1994, , 1006-1016.		0
971	New Generation Thrombolytic Agents. Developments in Cardiovascular Medicine, 1994, , 15-26.	0.1	0
973	Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?. Blood, 1994, 84, 680-686.	0.6	36
974	Expression of Tissue Plasminogen Activator in Cerebral Capillaries. Neurosurgery, 1995, 37, 955???961.	0.6	4
975	Studies on the Metabolic Fate of Modified Recombinant Tissue-Type Plasminogen Activator (E6010) (1): Blood or Plasma Concentration, Distribution, Metabolism and Excretion in Rats after a Single Intravenous Administration of l25I-E6010 in Comparison with l25I-Recombinant Tissue-Type Plasminogen Activator (rt-PA).. Drug Metabolism and Pharmacokinetics, 1996, 11, 556-584.	0.0	1
976	Invasive Therapie. , 1998, , 979-1004.		0
977	Rekombinante Proteine in der Behandlung der Koagulopathien. , 1998, , 288-307.		0
978	Investigation of Plazminogen Activator Effects on Progressive Ischemia into the Tissue Adjacent the Burn Injury By Tc-99m MIBI Scintigraphy and Autoradiography in an Experimental Local Burn Model. , 1999, , 505-509.		0
979	Localization of plasminogen activator inhibitor type 1 and 2 in preimplantation mouse development in vitro. Ankara Universitesi Veteriner Fakultesi Dergisi, 0, , .	0.4	0
980	Toward Better Understanding on How Group AStreptococcusManipulates Human Fibrinolytic System. , 0, , .		0
981	Structure and Functions of Fibrinogen and Fibrin. , 2008, , 3-26.		1
982	Chemistry, Pharmacokinetics, and Pharmacodynamics of T-PA, TNK and DSPA Alpha 1. , 1997, , 269-282.		0
983	Markers of Thrombosis and Fibrinolysis. , 1997, , 421-447.		0
984	Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests. Pediatric Research, 2003, 53, 333-337.	1.1	6

#	Article	IF	Citations
985	Biomarqueurs pronostiques LOE I/UC+++. , 2007, , 185-195.		0
987	Haemorrhagic Disorders. Clinics in Haematology, 1981, 10, 917-932.	2.2	1
988	Gastric pentadecapeptide BPC 157 in cytoprotection to resolve major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World Journal of Gastroenterology, 2022, 28, 23-46.	1.4	14
989	The physiology of hemostasis. Blood Coagulation and Fibrinolysis, 2022, 33, S1-S2.	0.5	8
990	Plg-RKT Expression in Human Breast Cancer Tissues. Biomolecules, 2022, 12, 503.	1.8	2
991	Hemostasis and Coagulation. , 0, , 27-42.		0
992	The pathophysiological role of fibrinolysis inhibitors. Research in Clinic and Laboratory, 1984, 14, 499-505.	0.3	1
993	Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. Journal of Thrombosis and Haemostasis, 2023, 21, 1043-1054.	1.9	4
994	Thrombolytic treatment of pulmonary embolism with APSAC. European Respiratory Journal, 1988, 1, 721-725.	3.1	7